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Risk Reduction Decision Making in Women with BRCA1/2 Gene Mutations
Heidi M. King
ABSTRACT
With technological advances in testing for gene mutations, a new population of
BRCA1/2 women is becoming aware of their increased risk for developing breast and/or
ovarian cancer. A salient issue these women face is which risk-reducing option to
choose. Little is known about the decision making factors underlying the choice of
prophylactic mastectomy for women with a BRCA1/2 mutation. To address this issue,
137 unaffected, positive BRCA1/2 gene mutation carriers (42 who opted for prophylactic
mastectomy, 95 who did not) served as participants. All women completed an on-line
battery that assessed the following theory-based decision making variables: advantages
and disadvantages of prophylactic mastectomy (normative decision theory), physician
recommendation (shared decision making theory), cancer worry (affect theory), and
information-seeking coping style. With the exception of information-seeking style
(p = .8715), the decision making variables of advantages and disadvantages of
prophylactic mastectomy, physician input, and cancer worry did have a significant
relationship with risk-reduction option chosen. Women who rated the advantages higher
than the disadvantages of prophylactic mastectomy (r = .31, p < .001), whose physician
had recommended prophylactic mastectomy exclusively (Χ2 = 11.85; p < .001), and who
reported higher cancer worry scores a month after receiving BRCA1/2 positive results
vi

(r = .28, p < .001) were more likely to have chosen prophylactic mastectomy. The
perceived impact (conflict, regret, cancer worry, and general well-being) of risk-reducing
option selected was also explored. The direction of these relationships indicates that
having chosen prophylactic mastectomy was associated with less decisional conflict
(r = -.38, p < .0001), decisional regret (r = -.58, p < .0001), depressive symptomatology
(r = -.19, p < .05), and cancer worry (r = -.39, p < .0001). The results suggest higher
assessments of advantages over disadvantages of prophylactic mastectomy, doctor
recommendation for prophylactic mastectomy exclusively, and higher cancer worry at
time of testing is associated with choosing the risk-reducing option of prophylactic
mastectomy. In addition, women who chose prophylactic mastectomy fared better
psychologically than those who did not. Continued research addressing decision making
variables and the impact of risk-reducing decisions may lead to improved understanding
on how best to approach these difficult decisions.

vii

Chapter One
Introduction
Due to technological advances in testing for gene mutations, a new population of
women is becoming aware of their increased risk for developing breast and/or ovarian
cancer. While this yet undiagnosed population is referred to as “unaffected” in the
medical community, these women have a unique set of medical and psychological needs.
The term “pre-vivors” was coined on the Facing Our Risk of Cancer Empowered, Inc.
(FORCE; www.facingourrisk.org) message board to describe this population of
individuals. FORCE is a non-profit organization created specifically to attend to the
issues arising in carriers of the Breast Cancer 1 and Breast Cancer 2 (BRCA1/2) gene
mutations which were discovered in 1994 (Miki et al.) and 1995 (Wooster et al.),
respectively. Approximately, 1 out of every 345 and 1out of 1000 people in the general
population in the United States are BRAC1/2 gene mutation carriers (Whittemore, Gong,
& Itnyre, 1997; Rubin, 2003). For certain populations this rate is even higher. For
example, people with Ashkenazi Jewish heritage, 1 out of every 40 people is estimated to
be BRCA1/2 carrier (Robles-Diaz, Goldfrank, Kauff, Robson, & Offitt, 2004). The most
salient issue for women who are carriers of the BRCA1 and/or BRCA2 gene mutations is
the increased risk of developing breast and/or ovarian cancer in their lifetimes.
Specifically, BRCA1 carriers have a 65% chance (95% confidence interval 44%-78%)
and BRCA2 carriers have a 45% chance (95% confidence interval 31%-56%) of being
1

diagnosed with breast cancer by age 70. Ovarian cancer incidence rates are slightly
lower with 39% (95% confidence interval 18%-54%) of BRCA1 carriers and 11% (95%
confidence interval 2.4%-19%) of BRCA2 carriers (Antoniou et al., 2003). Since testing
is considered appropriate for individuals with at least a 5% estimated chance of being a
BRCA1/2 gene mutation carrier (Armstrong, et al., 2000), a growing number of women
are faced with a series of medical decisions. Should she undergo genetic counseling?
Should she be tested and find out her BRCA1/2 test results? With whom, if anyone,
should she share the test results? Which type of risk-reducing strategy should she
pursue—surveillance, prophylactic surgery/surgeries, and/or chemoprevention? Each
decision comes with its own set of advantages and disadvantages. Because of the
difficulty involved in making these decisions, it is imperative that researchers, medical
providers, and patients understand the factors that go into the decision making process, as
well as the subsequent impact of these decisions (Schwartz, Peshkin, Tercyak, Taylor, &
Valdimarsdottir, 2005). This study will focus on the decision making factors underlying
the choice of a risk-reducing strategy for women at increased risk for developing breast
cancer due to the presence of a BRCA1/2 mutation. Specifically, the primary aim of this
study is to explore the relationship between four different theory-driven predictors (e.g.,
advantages and disadvantages of risk-reducing strategies, doctor recommendation, cancer
worry, and information-seeking style) and the decision to undergo prophylactic
mastectomy in unaffected carriers of a BRCA1/2 gene mutation. The secondary aim is to
explore how choice of risk-reducing strategy impacts these women through decisional
conflict, decisional regret, current cancer worry, and depressive symptomatology.
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First, a brief background on the motivation for undergoing, and the ambiguity
surrounding, genetic testing will be provided. Then, an overview of risk-reducing
strategies for breast cancer (surveillance, prophylactic mastectomy, and
chemoprevention) currently available to BRCA1/2 gene mutation carriers will be
reviewed. These topics are followed by a discussion of four decision making theories
that will provide a conceptual framework for studying risk-reducing decision making in
this new population of women: a) normative decision theory, b) shared decision making
theory, c) affect-based theory, and d) informational style theory. Finally, a review of
literature on the impact of risk-reducing strategy choice, such as decisional regret and
conflict, in this population will be provided.
Reasons for Pursuing Genetic Testing
Prior research suggests that people have four main reasons for obtaining genetic
counseling and BRCA1/2 testing (Pasacreta, 2003). The most popular reason has to do
with wanting the information in order to determine their child’s risk of inheriting the gene
(Lerman, Daly, Masny, & Balshem, 1994; Struewing, Lerman, Kase, Giambaressi, &
Tucker, 1995; Bluman et al., 1999; Lerman et al., 1997; Meijers-Heijboer et al., 2000).
Another factor motivating testing is to seek an answer to uncertainty about future risk of
developing cancer (Chaliki et al. 1995; Struewing et al., 1995; Bluman et al., 1999;
Lerman et al., 1997; Jacobsen, Valdimarsdottir, Brown, & Offit, 1997). A third
motivating factor for testing is to obtain information to inform decisions about which
risk-reducing strategy to pursue. With a 45-65% increased risk of developing breast
cancer (Antoniou et al., 2003) and an 11-39% increased risk of developing ovarian cancer
in their lifetimes (Antoniou et al., 2003; Lerman et al., 1994; Chaliki et al., 1995;
3

Struewing et al., 1995; Bluman et al., 1999; Lerman et al., 1997; Jacobsen et al., 1997),
many BRCA1/2 carriers are motivated to find ways to limit mortality from breast and/or
ovarian cancer. Finally, people have reported pursuing BRCA1/2 testing in order to make
informed decisions about marriage and/or childbearing (Lerman et al., 1994; Struewing et
al., 1995; Bluman et al., 1999; Lerman et al., 1997; Jacobsen et al., 1997).
Ambiguity of Test Results
The results of testing for BRCA1/2 gene mutations typically reflect ambiguity.
Unlike genetic testing for Huntington’s Disease, which almost always yields conclusive
results, testing for BRCA1 and BRCA2 may be less informative since sensitivity and
specificity of BRCA1/2 mutation testing is high. The genetic test for BRCA1/2 has the
following three potential results: 1) true positive, 2) true negative, or 3) inconclusive
negative. If a woman receives a positive result, she has a 45-65% chance of developing
breast and/or 11-39% ovarian cancer in her lifetime (Antoniou et al., 2003). Therefore,
not all people with a BRCA1/2 gene mutation will go on to be diagnosed with cancer.
Conversely, those without a gene mutation (a true negative result) may still develop
sporadic breast or ovarian cancer in their lifetime. Finally, an inconclusive negative
result may occur for several different reasons. A woman from a family in which no
family member has been tested for the gene mutation may have an as yet unknown gene
mutation that is not BRCA1/2 (Baum, Friedman, & Zakowski, 1997; Prasacreta, 2003), or
she may have a variant in BRCA1/2 that cannot be detected by the sequencing method
currently employed (Peshkin, DeMarco, Brogan, Lerman, & Isaacs, 2001). Therefore, all
three test results have varying levels of ambiguity with regard to whether or not a woman
will develop breast cancer. These varying levels may cause women with positive test
4

results to make decisions about future risk-reducing strategies differently from women
with true negative or inconclusive negative results. Therefore, the scope of this study
will be limited to a homogeneous sample of women who have received positive BRCA1/2
genetic test results.
Risk-Reducing Strategies
The risk-reducing strategies available to BRCA1/2 gene mutation carriers and
other women at high risk for breast cancer include the following: surveillance,
prophylactic mastectomy, and chemoprevention. The following section will summarize
the medical findings of these three strategies. Specifically, the sensitivity and specificity
of surveillance methods, the risk reduction rates for prophylactic mastectomy, and the
known results from chemoprevention studies will be reviewed.
Surveillance for Breast Cancer
The American Cancer Society Guidelines for Breast Cancer Screening (Smith et
al., 2003) suggest the following screening guidelines for women at average risk for breast
cancer: clinical breast exams every three years starting in their twenties and thirties and
annually for healthy women starting in their forties, the option to learn and conduct breast
self-exams, and mammography starting at age 40. For women at increased risk of breast
cancer, the American Cancer Society vaguely suggests modifications to the
recommendations above including earlier initiation of all screenings, shorter intervals
between screenings, and additional strategies like magnetic resonance imaging (MRI) and
ultrasound. Without sufficient evidence, they suggest that women decide on a course of
screening action via shared decision making with their doctors.
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The U.S. Preventive Services Task Force (USPSTF;
www.ahrq.gov/clinic/usptf/uspsbrgen.htm) only recommends mammography every one
to two years for women over 40. They neither recommend for or against regular clinical
breast exams or breast self-exams. For women who are carriers of the BRCA1/2
mutation, USPSTF recommends a discussion between patient and doctor about the
potential risks and benefits of chemoprevention. There is no conclusive research on how
women at increased risk for breast cancer should screen for the disease.
Observational studies have been conducted to examine the sensitivity and
specificity of surveillance for breast cancer in women with an increased risk for breast
cancer. One study is a non-randomized observational study of a BRCA1/2 mutation
cohort. Brekelmans et al. (2001) followed 1,198 women with elevated risk for
developing breast cancer. These women were divided into three groups based on their
risk status. The first group consisted of BRCA1/2 gene mutation carriers (n = 128). The
second group was categorized as high-risk (n = 621) because they had three or more first
or second-degree relatives with breast cancer diagnosed at an early age (< 50 years of
age). The third group of women was categorized as moderate-risk (n = 449) because they
had more than two relatives with breast cancer. The research protocol involved
instructions for monthly breast self-exams, clinical breast exams every 6 months, yearly
mammography, and MRI starting in 1995 for either gene mutation carriers or women
with dense breast tissue. After a mean follow-up of three years, the sensitivity of the
screening for gene mutation carriers was substantially less (56%) than for the overall
sensitivity of the screening program for high-risk women (74%). The small sample size
of gene mutation carriers is a limitation, so conclusions must be made cautiously.
6

However, results suggest that current surveillance methods may be less effective for
BRCA1/2 gene mutation carriers than other women at high or moderate risk.
Kuhl et al. (2005) conducted a surveillance cohort study with a sample of 529
women (n = 43 BRCA1/2 gene mutation carriers) with mixed levels of elevated risk for
contracting breast cancer, as well as with mixed cancer histories. The aim of this study
was to compare surveillance accuracies of the following methods: clinical breast exams,
mammography, breast ultrasound, and MRI. Each participant received semiannual
clinical breast exams and breast ultrasounds along with an annual mammography and
MRI. During the course of the study, 43 cases of breast cancer were diagnosed. Of
those, eight were diagnosed in mutation carriers. For women who were BRCA1/2 gene
mutation carriers, the sensitivity of MRI was 100% (versus 91% for the sample as a
whole) and the sensitivity of mammography was 25% (versus 33% for the sample as a
whole). The specificities were similar on all four imaging modalities for the gene
mutation carriers and the group as a whole. This study suggests that MRI allows for
earlier detection of breast cancer among women with BRCA1/2 gene mutations.
Warner et al. (2004) conducted a similar study comparing the specificity and
sensitivity of the four surveillance options (clinical breast exam, mammography,
ultrasound, and MRI) among women with BRCA1/2 mutations (n = 236) who did (39%)
or did not (60%) have a history of breast cancer. Each participant received all four
modalities each year, for one to three years. The following modalities are ranked in order
from highest to lowest in sensitivity: MRI (77%), mammography (36%), ultrasound
(33%), and clinical breast exam (9.1%). Specificity ranged from 95.4% (MRI) to 99.8%
(mammography). It was suggested that, for MRI to become part of standard care for
7

carriers of the BRCA1/2 gene mutations will require further research on mortality rates,
the ideal timing of this surveillance method, continued studies on the specificity of this
method, and the effectiveness of the MRI when conducted outside of a controlled
research setting (Robson & Offit, 2004).
In addition to the limitations cited in the Warner et al. (2004) study, additional
gaps in the literature on the surveillance options for unaffected BRCA1/2 gene mutation
carriers exist (Calderon-Margalit & Paltiel, 2004). These include heterogeneity of study
samples that include gene mutation carriers with or without a previous cancer diagnosis
as well as women at varying levels of high risk (Kuhl et al., 2005; Kuhl et al., 2000;
Brekelmans et al., 2001) and the lack of important outcome measures, including mortality
rates (Warner et al., 2004), grade and stage at diagnosis, and psychological well-being
(Kuhl et al. 2005; Kuhl et al., 2000; Brekalmans et al., 2001).
The advantages and disadvantages of choosing surveillance are not clear-cut. The
non-invasiveness of surveillance is a definite advantage. While surveillance is the least
invasive risk- reducing strategy, there may be some temporary psychological distress as a
result of inevitable false-positive test results (Lampic, Thurfjell, Bergh, & Sjödén, 2001;
Steggles, Lightfoot, & Sellick, 1998; Fentiman, 1998; Gilbert et al., 1998; Lowe,
Balanda, Del Mar, & Hawes, 1999). While there is promise that MRI may increase the
potential for early detection (Kuhl et al., 2000; Warner et al., 2004; Stoutjesdijk et al.,
2001; Tilanus-Linthorst, Obdeijn, Bartels, de Koning, & Oudkerk, 2000), it does nothing
to reduce the incidence of breast cancer. No studies could be found that looked at
surveillance in relation to breast cancer mortality, stage and grade, or quality of life
(Calderon-Maergalit & Paltiel, 2004).
8

Prophylactic Mastectomy
Prophylactic mastectomy, or the removal of healthy breast tissue, can be done in
various ways—subcutaneous mastectomy (removal of both breasts while keeping
overlying skin and nipple), total simple mastectomy (removal of both breasts and
overlying skin without axillary dissections), modified radical mastectomy (removal of
both breasts with overlying skin and axillary contents), and radical mastectomy (removal
of both breasts with overlying skin, pectoralis muscles, and axillary contents).
Regardless of the type of mastectomy performed, no form of mastectomy can completely
eliminate all of the breast tissue, and therefore no form can completely eliminate the risk
of breast cancer (Lostumbo, Carbine, Wallece, & Ezzo, 2005).
Several studies yielded similar findings with regard to the reduction of breast
cancer rates in women at high risk who opt for prophylactic surgery. Hartmann et al.
(1999) conducted a retrospective study of 214 women categorized as high-risk who had
opted for prophylactic mastectomy between 1960 and 1993. They were followed for a
median time frame of 14 years. Their untreated sisters (n = 403) served as the control
group. A 90% risk reduction was found for the high-risk group with only three women
who had opted for prophylactic surgery being diagnosed with breast cancer compared to
156 of their untreated sisters.
Hartmann et al. (2001) conducted a follow-up study in which they obtained blood
samples from their original sample of high-risk women. Twenty-six BRCA1/2 gene
mutation carriers were detected in the high-risk group. Of these women who had opted
for prophylactic surgery, none had developed breast cancer after 13.4 years of follow-up.
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Statistically, six to nine of these 26 women should have developed breast cancer
suggesting a risk reduction of 89.5% as in the original study.
Rebbeck et al. (2004) reported a similar risk reduction rate. In this prospective
study, 105 BRCA1/2 gene mutation carriers who opted for prophylactic mastectomy
alone, or in conjunction with prophylactic oophorectomy (i.e., the surgical removal of
healthy ovaries in an attempt to prevent ovarian cancer), were matched on age, gene, and
place of treatment with 378 BRCA1/2 gene mutation carriers who did not opt for
prophylactic surgery of any kind. The groups were followed for 5.5 years and 6.7 years,
respectively. At the end of the follow-up period, two women from the surgery group and
184 women from the non-surgery group had been diagnosed with breast cancer. This
represents a 95% reduction rate for women who had concurrent oophorectomy and a 90%
reduction rate for women who did not have a concurrent oophorectomy relative to the
non-surgery group.
While these studies suggest high rates of risk reduction for prophylactic
mastectomy, there remain some limitations to consider (Eisen, 1999). The Hartmann et
al. (1999, 2001) studies were made up of heterogeneous samples, with women of varying
degrees of risk being compared to one another. Through blood samples drawn from the
majority of the women at a later time (Hartmann et al., 2001), they found that
approximately 15% (26/176) of the women in the high-risk group were BRCA1/2 gene
carriers. Therefore, approximately 85% of the sample was presumably not at the 45-65%
increased risk for hereditary breast cancer. While some lives were saved by use of
prophylactic mastectomy (Hartmann et al., 1999; Rebbeck et al., 2004), hundreds of
women may have undergone surgery unnecessarily. Finally, self-selection bias may be a
10

problem with these studies, especially if baseline risk differs between surgical and
nonsurgical groups (Klaren, van’t Veer, van Leeuwen, & Rookus, 2003; CalderonMargalit & Paltiel, 2004).
Chemoprevention and Breast Cancer
Chemoprevention, or the use of medication as a risk-reducing strategy for cancer,
is currently being studied in BRCA1/2 gene mutation carriers. Tamoxifen, one of the
most studied medications, is already an established adjuvant treatment option for women
diagnosed with cancer (Heuson, 1976; Margreiter & Wiegele, 1984). It is either
prescribed alone or along with chemotherapy and has been shown to reduce the risk of a
future, secondary cancer diagnosis in the unaffected breast (Rutqvist et al., 1991; Fisher
& Redmond, 1991).
In the Breast Cancer Prevention Trial (BCPT; Fisher et al., 1998), 13,338 women
at high risk for cancer were randomized into a tamoxifen group or a placebo group for
five years. For the purposes of this study, high-risk was defined by one of the following
three criteria: 1) age over 60 years, 2) age between 35 and 59 years with a greater than
1.66% risk of cancer as predicted by the Gail model, or 3) a history of lobular carcinoma
in situ (i.e., benign change in the cells of the milk duct that suggest an increased risk for
breast cancer in the future). Results of the study suggest that tamoxifen reduces the
occurrences of both invasive and noninvasive breast cancer. Specifically, this medication
reduced the risk of invasive cancer by 49% (p < .01) and noninvasive cancer by 50% (p <
.01). At the time the study was conducted, blood samples were taken from each
participant in order to be assessed for BRCA1/2 gene mutations in the future. However,
results from those blood samples suggest a low number of actual BRCA1/2 gene mutation
11

carriers in this study. King et al. (2001) studied the 288 women who had been diagnosed
with breast cancer while participating in the BCPT. Of this sample, 6.6% were BRCA1/2
gene mutation carriers. Results suggest that tamoxifen reduced breast cancer incidence in
women with BRCA2, but the results were not clear for BRCA1. The sample size was too
small to make any generalizations. Further research is needed in the area of
chemoprevention for breast cancer in BRCA1/2 gene mutation carriers.
Decision Making Theories
What factors predict risk-reducing decisions for BRCA1/2 carriers? In a review of
decision making factors by Schwartz, Peshkin, et al. (2005), risk reduction rates alone did
not predict risk-reducing strategy. If that were the case, the majority of women would
pursue prophylactic mastectomy because of its 90% risk reduction rate compared to a 0%
risk-reduction for surveillance (Rebbeck et al., 2004, Hartmann et al., 1999, 2001) and an
unknown reduction rate for chemoprevention (Fisher et al., 1998; King et al., 2001).
However, in three risk-reducing decision studies with BRCA1/2 gene mutation carriers
conducted in the U.S., only 3% of women had opted for mastectomies at one year
(Lerman et al., 2000; Peshkin et al., 2002) and none of the women had opted for
mastectomies at two years post-genetic testing (Botkin et al., 2003). Therefore, in
looking beyond the numbers, it will be important to consider other factors that may go
into the selection of risk-reducing strategies. This study will focus on the following
theory-based predictors in the selection of mastectomy or no mastectomy in this
population: 1) analysis of advantages and disadvantages, 2) doctor recommendation,
3) affect, and 4) information-seeking style.

12

Normative Decision Theory
Normative decision theory suggests that individual’s decisions are made by a
logical, unbiased, measured assessment of the advantages and disadvantages surrounding
a choice. This theory is exemplified by the traditional model of genetic counseling.
Cancer genetic counseling typically consists of an unbiased, nondirective relaying of
information over three sessions. In the first session, pretest information is gathered,
advantages and disadvantages of testing are presented, and the nature of the test and its
results are explained. Patients are then asked to make a decision about testing. If they
decide to test, there is a second meeting where a DNA sample is obtained. Finally,
during the third session, test results are provided (Schwartz, Peshkin, et al., 2005). It is
believed that if comprehensive and accurate information is provided during genetic
counseling, the patient will utilize this information in combination with their personal
preferences to arrive at a personally satisfactory decision about whether or not to engage
in genetic mutation testing. The preferred outcome is then an informed decision that
reflects a person’s preferences. This theory can be extrapolated to involve decisions that
people make about risk-reducing strategies following genetic testing.
The following two studies exemplify the normative decision making theory as
applied to genetic counseling. Armstrong et al. (2000) retrospectively studied 211
women from the University of Pennsylvania Breast and Ovarian Risk Evaluation
Program (BCREP). The BCREP is a university-based, multidisciplinary program in
Philadelphia designed to provide women with individualized breast cancer risk
assessment, as well as the option to pursue genetic counseling and testing. These women
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were categorized into the following two groups based on gene mutation testing: those
who had undergone BRCA1/2 testing (n = 125) and those who decided against testing
(n = 86). As predicted by the normative decision theory, women who ranked the
beneficial factors for genetic testing significantly higher were more likely to undergo
genetic testing. These beneficial factors included information for family members (p <
.01), learning about cancer risk (p = .01), as well as help in decision making about both
prophylactic mastectomy (p = .01) and prophylactic oophorectomy (p < .01).
Conversely, women who rated negative effects of testing, such as insurance (p = .04) or
job discrimination (p = .01) significantly higher were less likely to undergo genetic
testing.
Lerman et al. (1996) conducted a prospective study that used principles from
normative decision theory. This was accomplished by use of a base measure of decision
making predictors for genetic testing. Information about 192 participants at high risk for
the BRCA1 mutation was collected via telephone interviews conducted one to two
months prior to testing. As expected, participants who reported more benefits of genetic
testing at baseline were significantly more likely to get tested.
The principles of the normative decision theory have also been applied to the
study of choice of risk-reducing strategies. Because of a lack of studies looking
specifically at the advantages and disadvantages of prophylactic mastectomy among
BRCA1/2 gene mutation carriers, a study looking at oophorectomy decision making is
reviewed. In a cross-sectional, retrospective study, a group of high-risk women (n = 30)
who had opted for prophylactic oophorectomy between 1-5 years previously were
matched to high-risk women who had opted for surveillance (n = 28) during the same
14

time frame (Fry, Rush, Busby-Earle, & Cull, 2001). They were all assessed as to how
they rated the advantages and disadvantages of oophorectomy. Women in the surgical
group rated the following decision making factors significantly higher
(p < .05) than women in the surveillance group: the desire to reduce cancer worry, desire
to reduce the risk of ovarian cancer, and worries about the effectiveness of ovarian
screening. This study exemplifies the normative decision theory, with differing ratings of
advantages and disadvantages predicting surgical group membership.
Shared Model of Decision Making
The shared decision model is an outgrowth of the normative decision theory. It
incorporates the view that patients are consumers of medical care and both desire and
have a right to actively participate in decision making concerning treatment and riskreducing strategies. Although the definition, timing, and purpose of the shared decision
model is not universally agreed upon (McNutt, 2004), a broad definition typically
involves comprehensive education on the risks and benefits that are part of the normative
decision making theory. In addition, it includes an active attempt to engage patient
values in the decision making process. This is often accomplished via decision aids such
as brochures, videos, computer software, as well as physician input. Therefore, in this
model, effective decision making is conceptualized as providing the patient with both
objective medical information incorporated with his/her subjective values and opinions
about the trade-offs that need to be made (Coulter, 2002).
Before reviewing if women at-risk for breast cancer incorporate their physician’s
opinion into their decisions to get genetic testing or pursue surgery as a risk-reducing
strategy, the following studies review the opinions of health care providers regarding
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these decisions. One hundred sixty-three genetic counselors from the National Society of
Genetic Counselors Special Interest Group in Cancer were surveyed through the mail.
They were asked if they would personally undergo genetic testing if they were found to
be at 50% risk for carrying the BRCA1/2 mutations (Matloff et al., 2000). They were
further asked what risk-reducing strategy they would pursue if they were 35 years of age,
had completed their families, and were found to be a carrier. Eighty-five percent of
counselors stated they would pursue genetic testing with a 50% risk. They cited reasons
for choosing testing that were consistent with those of actual women in this situation who
opted for testing (Lerman et al., 1994; Chaliki et al., 1995; Struewing et al., 1995;
Bluman et al., 1999; Lerman et al., 1997; Jacobsen et al., 1997; Meijers-Heijboer et al.,
2000). Eight percent of the genetic counselors stated they would decline testing because
of fear of discrimination and knowing this information would not alter plans for current
medical management. With regard to risk-reducing strategies, a majority of the sample
(68%) stated they would pursue oophorectomy while 25% stated they would pursue
mastectomy. These results are higher than actual BRCA1/2 carriers’ reports of their
intentions (17% for mastectomy and 33% for oophorectomy) reported by Lerman et al.
(1996). However, they are consistent with other studies of doctors in this field (Geller et
al., 1998; O'Malley, Klabunde, McKinley, & Newman, 1997). Stefanek (1995) surveyed
female radiation and medical oncologists on the course of risk-reducing strategy they
would choose if they had a known 35-40% chance of breast cancer risk. In this sample,
50% of the radiologists and 86% of the medical oncologists stated they would opt for
prophylactic bilateral mastectomy.
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While no studies could be found that directly looked at the relationship between
physician opinion and prophylactic mastectomy in BRCA1/2 gene mutation carriers,
studies looking at physician opinion of genetic testing and treatment outcome in women
for varying risk of breast cancer were identified. Based on the findings from these
studies, one may extrapolate the way in which physician opinion may influence a
BRCA1/2 gene mutation carrier’s decision to pursue prophylactic mastectomy.
Women with extensive family histories for breast cancer are potential candidates
for the shared decision model at two different points. The first decision point involves
whether or not a woman should pursue genetic testing. Armstrong et al. (2002)
conducted a retrospective study with 335 women involved in the University of
Pennsylvania Breast and Ovarian Risk Evaluation Program (BCREP). As discussed
earlier, the BCREP is a multidisciplinary program designed to provide women with
individualized breast cancer risk assessment, genetic counseling, and genetic testing.
After making the decision whether or not to undergo genetic testing, each woman
received a packet in the mail asking her to retrospectively state if she would have liked to
have known the opinion of her primary care doctor and the opinion of her BCREP doctor
(yes, no, or unsure). This approach is a challenge to the traditional, non-directive
approach typically offered in genetic counseling because it brings in the opinions of the
physician. In the sample as a whole, 33% pursued BRCA1/2 testing while 67% did not.
A majority of the women in this study (77%) wanted to know the opinions of the BCREP
doctors. In addition, forty-nine percent wanted to know the opinions of their primary
care doctors. Women who chose not to be tested were more likely to have wanted the
opinions of their doctors. This study suggests that all the needs of women undergoing
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gene mutation testing may not be met by the traditional approach to genetic counseling.
The retrospective nature of this study is an obvious limitation, as well as the inability to
generalize from the data because of the homogeneous sample of white, highly educated
women that participated in this program.
Schwartz, Lerman, et al.’s prospective study (2005) of the utilization of BRCA1/2
mutation testing in women newly diagnosed with breast cancer supports findings from
Armstrong et al.’s (2002) study. Specifically, 211 women completed a structured phone
interview assessing basic sociodemographic variables, psychological variables, medical
variables, as well as whether or not their oncologist recommended BRCA1/2 mutation
testing. Then, they underwent a traditional, nondirective genetic counseling session,
testing, and feedback sessions as desired. Results of a logistic regression model
suggested that doctor recommendation was a contributing factor in determining whether
or not women pursued genetic mutation testing. Patients who received a doctor’s
recommendation were three times more likely to pursue genetic testing. Though not part
of the nondirective genetic counseling model, doctor recommendation emerged as a
deciding factor. The findings from these two studies on preference to know doctor
recommendation for genetic testing suggest the possibility that preference for doctor
recommendation will also be true when choosing a risk-reducing strategy such as
prophylactic mastectomy.
Van Roosmalen et al. (2004b) tested the shared decision model in an intervention
study with 88 women who had undergone free BRCA1/2 genetic testing. Half of the
group was randomized to receive a shared decision model intervention, while the other
half of the sample received usual care. The intervention consisted of three sessions with
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a counselor over three weeks with decisional aides. Health states following treatment
options were written on laminated cards. Patients rank-ordered these cards and then
discussed the value of each of the health states using time as a unit of comparison.
Outcome variables included treatment choice, decision related outcomes such as strength
of treatment preference, decision uncertainty, perceived participation in decision making,
weighing treatment choice, perceived preference of the specialists, and support and
advice from specialists, as well as well-being. Although there was no effect on
preventive treatment choices between the groups, women in the intervention group
reported significantly stronger preferences (p = .02) and a stronger belief that they had
weighed the advantages and disadvantages more effectively (p = .01). Women in the
intervention group also felt that their specialists had a preference for one breast treatment
over another (p < .01). While not significant (p = .09), women in the intervention group
did report a desire for more support and advice about treatment choices for breast cancer
from their specialists. The results suggest women who were given the chance to
participate more fully in the decision making process felt that their specialists had an
opinion about their treatment and were interested in their specialists’ support and advice
to a higher degree than those who did not partake in the decision making process as
much. In addition to these treatment and decision outcomes, there were significant longterm effects on well-being. Women in the intervention group reported less intrusive
thoughts (p = .05) and better general health (p = .01).
Van Roosmalen et al.’s (2004b) study on shared decision making adds to the
current literature by broadening the scope of treatment outcomes addressed; specifically,
patient well-being (as measured by intrusive thoughts and general health) and decision
19

related outcomes (such as strength of treatment preference, decision uncertainty,
perceived participation in the decision making, and weighting of treatment choice).
These issues were addressed in addition to preventive treatment choice alone.
Limitations of this study included the time and labor intensiveness of the intervention
evaluated. While the above review suggests the desire for physician input about genetic
testing and treatment choices, there is a need in the literature to address how physician
input specifically relates to choice of prophylactic mastectomy in women who are
BRCA1/2 carriers.
Affect-Based Decision Making
As shown above, women at varying risks for breast and ovarian cancers appear to
be making decisions by weighing the advantages and disadvantages of risk-reducing
options, as well as doctor recommendation. In addition, several studies have shown that
cancer-specific distress may be an important factor in making decisions about genetic
testing, as well as risk-reducing strategies. Specifically, cancer-related anxiety or fears
appear to be a motivating factor for women to pursue testing or risk-reducing options
more aggressively. The affect heuristic (Slovic, Finucane, Peter, & MacGregor, 2004;
Ubel & Lowenstein, 1997, Schwartz, Peshkin, et al., 2005) may be a potential
explanation for this phenomenon. This theory posits that people making decisions under
duress will rely more on how they feel affectively than on other decisional factors.
While no studies that looked directly at the relationship of affect in BRCA1/2 gene
mutation carriers to pursuit of prophylactic mastectomy could be found, a review will be
provided of studies using at-risk women with the following treatment outcomes: decision
to undergo genetic testing and intentions to pursue mastectomy. Based the findings from
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these studies, one may extrapolate the way in which affect may influence BRCA1/2 gene
mutation carriers’ decisions to pursue prophylactic mastectomy.
The first study to be reviewed examined cancer-specific distress as a predictor for
pursuit of BRCA1 testing. The study involved 149 women and men with hereditary
breast ovarian cancer (HBOC) syndrome, or multiple family members in multiple
generations with early onset of breast and/or ovarian cancers (Lerman et al., 1997).
Blood samples had been collected from most of the participants, years previously, in an
effort to isolate the BRCA1 gene (Feuntaun et al., 1993). These participants were
contacted for the present study with notification that their test results were being made
available. If they decided to participate, they would undergo a 40-minute phone
interview, an education session, and if desired, receive their BRCA1 results at a disclosure
session. Baseline measures of general distress (Center for Epidemiologic Studies
Depression Scale--CES-D; Radloff, 1977) and breast-cancer specific distress (Intrusion
Subscale of the Impact of Events Scale—IES; Horowitz, Wilner, & Alvarez, 1979) were
administered. Fifty-eight percent of the participants requested testing results, while 42%
declined their results. In a hierarchical logistic regression analysis, cancer-specific
distress was entered after sociodemographic variables and objective risk and was found to
significantly improve prediction of receipt of BRCA1 test results (p < .05). People with
higher cancer-related distress scores were more likely to obtain their test results.
Van Dijk et al. (2003) looked at the relation of breast cancer worry to intentions to pursue
prophylactic mastectomy in women at risk for familial breast cancer. As part of a larger
study, a mixed sample of affected and unaffected women with varying rates of risk (n =
241) completed a questionnaire including two items from Lerman et al.’s (1991) Cancer
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Worry Scale (CWS) both before and after a genetic counseling session in which their
familial lifetime cancer risk was revealed. Higher levels of breast cancer worry at precounseling independently predicted intention to pursue prophylactic mastectomy (β =
0.32; p < .01), while objective risk information did not (p = .78).
In the following hypothetical, vignette study looking at decision factors, women
with a first degree relative diagnosed with breast cancer (n = 129) were compared to
women without a first degree relative with breast cancer (n = 104) (Stefanek, Enger,
Benkendorf, Flamm Honig, & Lerman, 1999). Each participant read a vignette about a
woman diagnosed with breast cancer and was asked to answer questions on whether she
would choose prophylactic mastectomy or close screening given this fictitious woman’s
history. Women who reported higher levels of breast cancer worry (measured by one
item) were more likely (p < .05) to voice an interest in prophylactic mastectomy.
Information Style Theory
Miller, Roussi, Caputo, and Kruss (1995) have identified two main informationseeking styles, monitoring and blunting, that relate to the way that individuals under
stress apply information. For example, a medical patient who incorporates a monitoring
style seeks out, focuses on, and amplifies threatening cues about her medical situation.
She is attuned to the negative, dangerous, or painful portions of her illness. Conversely, a
medical patient with a blunting style avoids, minimizes, and actively distracts herself
from any threatening information, symptoms, or cues.
The following two studies focus on information-seeking style and genetic
counseling decisions for women at high risk for breast and/or ovarian cancer. Before
genetic testing for the BRCA1/2 gene mutation was available, Lerman et al. (1994)
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conducted a cross-sectional study with 121 first-degree relatives of ovarian cancer
patients with no personal cancer history. The aims of this study were to assess factors
that were related to intentions to test, along with expectations about the anticipated
impact of such testing. The Miller Behavioral Style Scale (MBSS; Miller, 1987) was
used to study information-seeking style. A majority of women (75%) expressed interest
in testing. As expected, being a woman who employed a monitoring coping style was
positively associated with an anticipated negative impact of testing. Specifically,
monitors expected more of the negative consequences of testing including depression,
anxiety, and decreased quality of life.
Schwartz, Lerman, Miller, Daly, and Masny (1995) studied 103 unaffected firstdegree relatives of women with ovarian cancer assessed via a phone interview and selfreport questionnaires, including the MBSS. As predicted in this study, being a woman
with a monitoring coping style was positively related to higher perceived risk, intrusive
thoughts, and psychological risk. In addition, high monitors overestimated their risk for
ovarian cancer regardless of their actual risk.
No studies to date could be found looking at the role that this monitoring-blunting
information-seeking style plays in actual choice of risk-reduction strategies by BRCA1/2
carriers. However, given the findings of overestimation of risk (Schwartz et al., 1995)
and psychological risk (Lerman et al., 1994; Schwartz et al., 1995) reported in genetic
testing with this population, high monitoring women may be more likely to opt for
prophylactic mastectomy.
Gaps in the Literature
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The studies reviewed above have demonstrated that assessment of advantages and
disadvantages, physician opinion, affect, and information-seeking appear to influence
decisions made by women at increased risk for breast cancer. However, limitations exist
in the current literature on predictors of decision making about prophylactic mastectomy
for women who have tested positive for the BRCA1/2 gene mutations. Specifically, the
samples reviewed are heterogeneous. They have included women with varied risk levels
(Van Dijk et al., 2003; Stefanek et al., 1999) and women with varied cancer histories
(Van Dijk et al., 2003). In addition, the studies reviewed for the most part have not
investigated risk-reducing strategy decisions in general, or prophylactic mastectomy
decisions in particular. Finally, the studies reviewed have failed to look at the predictive
value of the four variables of assessment of advantages and disadvantages, physician
opinion, affect, and information styles simultaneously.
Perceived Impact of Risk-Reducing Choice
The second aim of this study focuses on the perceived impact of risk-reducing
choice. Connolly and Reb (2005) identified some overarching, definitional features of
the construct of regret. Specifically, regret involves both a cognitive and affective
evaluation of two or more choices. Though an aversive feeling, it differs from
disappointment or general negative affect. For the purpose of this study, the focus of the
potential regret will be the type of risk-reducing alternative chosen (i.e., mastectomy or
no mastectomy).
No studies could be found that compared decisional regret, decisional satisfaction,
or decisional conflict among women with BRCA1/2 gene mutations who chose
prophylactic mastectomies versus women who opted for surveillance (Lostumbo et al.,
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2005). However, a few studies have looked at decisional regret or satisfaction among
women with unknown mutational status who have chosen prophylactic mastectomy.
Borgen et al. (1998) looked at regret in a sample of 370 women who had undergone
bilateral mastectomies between 1945 and 1996 and who signed up to be part of the
National Prophylactic Mastectomy Registry. Five percent of the women (n = 21)
reported regret with approximately half of these women (n = 10) stating they would not
have chosen surgery again. The discussion initiator of surgery (physician versus patient)
was the only statistically significant variable (p < .05) that distinguished women who had
regrets from those who did not. Specifically, more women whose physicians initiated
conversations about surgery (19/255) had regrets versus women who initiated
conversations about surgery themselves (2/108). Overall, however, the majority of
women (n = 349) did not express regret over undergoing prophylactic mastectomies.
One study (Stefanek, Helzlsouer, Wilcox, & Houn, 1995) assessed the satisfaction
level of 14 women with a family history of breast cancer who opted for prophylactic
mastectomy in the past 6-30 months (M = 9.4). Satisfaction in the following areas were
assessed by a 5-point Likert scale: recovery time physically and emotionally, degree of
discomfort and expectation of discomfort, support system as it pertained to their decision,
overall satisfaction with decision, reconstruction, and proclivity to recommend to a
friend. Satisfaction was high in all areas with the exception of reconstruction. This
study will examine decisional regret and conflict in women who are BRCA1/2 gene
mutation carriers.
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Aims
The current study has two aims. The first aim is to explore the relationship
between a set of theory-driven decision making variables and the actual treatment
decisions made by a group of healthy, unaffected women who have tested positive for a
BRCA1/2 gene mutation. Because the ideal treatment for carriers of the BRCA1/2 gene
mutation is yet unknown (Marchetti et al., 2004), women are forced to make their
decisions on factors other than strict medical information. The four variables addressed
are the advantages and disadvantages of prophylactic mastectomy (normative decision
theory), doctor recommendation (shared decision making theory), cancer worry (affect
theory), and information-seeking coping style. For purposes of analysis, the type of
treatment chosen is classified as whether or not prophylactic mastectomy was performed.
The second aim is to explore the perceived impact (conflict, regret, cancer worry,
and general well-being) of the treatment option selected. The study will look at the
relationship of decisional conflict, decisional regret, cancer worry, and depressive
symptomatology in relation to the treatment options women selected.
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Decision Making Hypotheses
The first hypothesis posits that the way in which individuals assess the pros and cons of
prophylactic mastectomy will be related to the type of treatment chosen.
1. Women who rate the pros of prophylactic surgery greater than the cons of
prophylactic surgery will be more likely to have chosen surgery.
Conversely, women who rate the cons of surgery greater than the pros of
surgery will be more likely to have not chosen surgery.

The second hypothesis posits that the treatment chosen will be related to
recommendation of that treatment by a physician.
2. If a physician had recommended prophylactic mastectomy, women will have
been more likely to have chosen prophylactic mastectomy.

The third hypothesis posits that levels of cancer worry will be related to the type
of treatment chosen.
3. Women with higher levels of reported cancer worry at the time of genetic
testing will be more likely to have chosen prophylactic mastectomy than
women with lower levels of reported cancer worry at the time of genetic
testing.
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The fourth hypothesis posits that information-seeking style will be related to
treatment choice.
4. Women with greater tendencies to use a monitoring information-seeking style
will be more likely to have chosen prophylactic surgery.

Depending on results of these hypotheses testing, exploratory analyses will be
undertaken to examine which variable(s) accounts for the most variance in the treatment
decision. Specifically, the analyses will seek to identify which variable(s) from the four
decision making models provide(s) the best fit for predicting treatment choice in
BRCA1/2 positive, healthy, unaffected women.

Perceived Impact Hypotheses
The fifth set of hypotheses explores the perceived impact of treatment choice.
5A. Women who chose prophylactic surgery will experience less decisional
conflict than women who have not chosen prophylactic surgery.
5B. Women who chose prophylactic surgery will experience less decisional
regret than women who have not chosen prophylactic surgery.
5C. Women who chose prophylactic surgery will experience lower levels of
depressive symptomatology than women who have not chosen prophylactic
surgery.
5D. Women who chose prophylactic mastectomy will experience lower levels of
cancer worry than women who have not chosen prophylactic mastectomy.
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Chapter Two
Method
Participants
Women without a history of cancer who had tested positive for gene mutations in
BRCA1/2 were solicited via the website for Facing Our Risk of Cancer Empowered, Inc.
(FORCE; www.facingourrisk.org). FORCE is a non-profit organization designed to
educate, support, raise awareness, and promote research in the area of genetic
susceptibility for breast and ovarian cancers. Demographic data made available about
new FORCE website subscribers between June and August of 2006 (approximately 420
people) suggest that the majority of subscribers are women between the ages of 36 and 60
(97%), Caucasian (89%), with no personal history of cancer (57%). Of the women with
no personal history of cancer, 25% reported having had genetic testing.
Between December 2006 and June 2007, a link to this study’s on-line survey was
advertised on the FORCE website message board, as well as via website pop-ups. In
addition, five e-mail reminders about the study were distributed to individuals who
subscribe to the FORCE newsletter.
In order to be considered eligible for the study, participants had to be women at
least one year post genetic testing. By surveying women at least one year post-testing,
we wanted to allow for a reasonable amount of time for these women to make and act on
decisions regarding risk-reducing options. In addition to being tested and receiving their
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positive genetic test results at least one year prior to completing the survey, these women
also met the following eligibility criteria: 1) be at least 18 years of age, 2) be proficient
in English, 3) have not undergone oophorectomy as a risk-reducing cancer strategy,
4) have not received chemoprevention as a risk-reducing strategy, and 5) have no
personal history of cancer (with the exception of basal cell carcinoma).
Procedure
The survey was initially piloted on two women who met study criteria. The
executive director of FORCE selected pilot participants. The purpose of piloting was to
verify the estimated survey completion time and ensure that the questions were clearly
worded and fully understood. Eligible pilot participants were contacted by phone. A
scripted format (Appendix A) was followed on the telephone in order to describe the pilot
study, ask questions to confirm pilot study eligibility, and obtain verbal informed
consent. Upon receiving verbal consent, each participant was mailed the following
materials: two copies of written informed consent (Appendix B), the survey web address,
and a self-addressed stamped envelope. Each woman was asked to return one signed
copy of the informed consent and provide three potential times that they would be
available by phone after completing the survey. Upon receipt of the informed consent,
the participants were contacted by phone and debriefed. Using the Question Appraisal
System (QAS99; Center for Disease Control and Prevention, 1999), each item and set of
instructions that was not part of standardized measures was reviewed. The QAS99
systematically assesses each item in all of the following areas: instructions, clarity,
assumptions, knowledge/memory, sensitivity/bias, response categories, and
miscellaneous problems. After collecting pilot data, minor changes including the
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addition of one question and the clarification in the instructions for a section regarding
attitudes about breast self-examination were made. One supplementary question was
added about cosmetic surgery. In addition to inquiring if women underwent cosmetic
surgery, a question was added about the specific kind of cosmetic surgery (e.g.,
reconstruction after prophylactic mastectomy, reduction, or augmentation). In addition,
the instructions in front of five questions regarding attitudes about breast selfexamination were modified
After the survey had been successfully piloted, interested parties were then able to
click onto a secure link embedded into the FORCE website to complete the on-line
survey. The first screen described the nature of the study and asked a series of questions
evaluating eligibility criteria (Appendix C). If eligibility criteria were not met,
individuals were directed to a screen thanking them for their interest but informing them
that they were not eligible for the study. If eligibility criteria were met, a page with all
the information relevant to provide informed consent was provided (Appendix D). Per
IRB regulations for web-based studies, women provided their consent by clicking on an
“I agree” button. If eligibility criteria were met and consent provided, individuals were
then able to proceed through the battery of measures (Appendices E-M). All data was
housed on a secure server.
It was anticipated that substantially more women who volunteered to participate
would not have undergone prophylactic mastectomy. After extensive recruitment efforts,
usable data were collected on 137 eligible women. As anticipated, more surveys were
received from women who had not undergone prophylactic mastectomy (95 who did not
opt for prophylactic and 42 who did opt for prophylactic mastectomy). Because these
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two groups did not differ statistically by age (p = .53) or time since genetic testing (p =
.77), this entire sample of eligible participants (N = 137) was used in the analyses rather
than the proposed matching procedure that would have reduced the total sample size to
84 (42 in each group).
Measures
The on-line survey battery assessed demographic and clinical information,
perceived advantages and disadvantages of prophylactic mastectomy, and physician
recommendations regarding risk-reducing option. In addition, valid and reliable
measures of cancer worry, information-seeking style, decisional conflict, decisional
regret, and depressive symptomatology were included. The battery took approximately
25 minutes to complete.
Demographic and Clinical Information. A standardized self-report measure was
used to obtain demographic and clinical information (Appendix E). The following
demographic information was obtained from all participants: age, race, ethnicity,
income, educational level, and marital status. The clinical information collected included
menopausal status, height and weight, family history of breast and ovarian cancers, time
since genetic testing, current perceived breast cancer risk, and intentions to undergo an
oophorectomy. In addition, information was collected as to whether or not these women
chose to share their positive genetic results with their primary care doctors. Time since
surgery and perceived breast cancer risk prior to prophylactic mastectomy was also
collected from women who had undergone prophylactic mastectomy. In addition to
intentions to undergo prophylactic mastectomy in the future, information on surveillance
behavior history and future surveillance behavior intentions was gathered from the group
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who had not opted for prophylactic mastectomy. Specifically, we collected information
on if and how often they performed breast self-exams and underwent clinical breast
exams, mammography, and MRI for the detection of breast cancer.
Decisional Balance Scale for Prophylactic Mastectomy. The Decisional Balance
Scale for Prophylactic Mastectomy (Appendix F) assessed the perceived advantages and
disadvantages of undergoing prophylactic mastectomy. The scale was specifically
designed for this study and consists of 8 items (4 worded as advantages or “pros”, 4
worded as disadvantages or “cons”). Items for this measure were taken from the
literature on the assessment of advantages and disadvantages of prophylactic mastectomy
by women at increased risk for breast cancer (Claes et al., 2005). Women were asked to
state the degree to which they had considered these items when deciding whether or not
to undergo prophylactic mastectomy. Responses were provided on a 5-point Likert scale
ranging from “strongly agree” to “strongly disagree.” Coeffecient alphas calculated in
the present study were .48 for the advantages scale and .44 for the disadvantages scale.
Physician Input. Participants answered questions as to whether or not one or
more doctors made recommendations to them about which risk-reducing strategy they
should pursue (Appendix G). They were also asked to state the recommendation(s)
made.
Cancer Worry. The Cancer Worry Scale (CWS; Lerman et al., 1991; Lerman,
Kash, & Stefanek, 1994) is a 4-item scale measuring the degree to which worrying about
breast cancer hinders daily functioning (Appendix H-I). Participants rate each item on a
4-point Likert scale from “not at all or rarely” to “a lot.” In several studies looking at
womens’ worries and concerns about breast cancer, the CWS is recognized as having
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good internal consistency and test-retest reliability (Bowen et al., 2003; Rees, Fry, Cull,
& Sutton, 2004). Women in this study were asked to complete this measure both
retrospectively (Appendix I; one month after receipt of BRCA1/2 results) as well as for
the past month (Appendix H). Coefficient alphas were .84 for current reports and .87 for
retrospective reports of cancer worry.
Decisional Conflict. The Decisional Conflict Scale (DCS; O’Connor, 1995) is a
16-item measure designed to assess uncertainty experienced by a person about an
undertaking (Appendix J). Participants rate each item on a 5-point Likert scale ranging
from “strongly agree” to “strongly disagree.” Scores are summed and transformed to
yield a total score ranging from 0 (no decisional conflict) to 100 (extremely high
decisional conflict). The validity and reliability of the DCS has been demonstrated in
prior research (O’Connor, 1995; Song & Sereika, 2006; University of Ottawa, 2006 ).
Coefficient alpha for the total score in the present study was .94.
Decisional Regret. The Decision Regret Scale (O’Connor et al., 1998) is a 5-item
measure designed to assess the degree of remorse or distress over a past decision
(Appendix K). Participants rate each item on a 5-point Likert scale ranging from 1
“strongly agree” to 5 “strongly disagree.” Scores are summed and transformed to yield a
total score ranging from 0 to 100. The validity and reliability of the Decision Regret
Scale has been demonstrated in prior research (Brehaut et al., 2003; University of
Ottowa, 1996). Coefficient alpha in the current study was .91.
Depressive Symptomatology. The Center for Epidemiologic Studies, Depression
Scale (CES-D; Radloff, 1977) is a 20-item self-report measure developed to assess
current depressive symptomatology (Appendix L). Items are rated on a 4-point Likert
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scale ranging from 0 (rarely or none of the time) to 3 (most or all of the time).
Participants are asked to respond to each item based on the degree to which they have
been experiencing each symptom in the past week. Total scores range from 0 to 60, with
higher scores indicating more severe depressive symptomatology. The validity and
reliability of the CES-D has been demonstrated in numerous studies (Devins, Orme,
Costello, & Binik, 1988; Hann, Winter, & Jacobsen, 1999; Weissman, Prusoff, &
Newberry, 1975). Coefficient alpha in the current study was .93.
Information-Seeking Style. The Miller Behavioral Style Scale (MBSS; Miller,
1987) measures differences in the way individuals either seek out (i.e., monitor) or avoid
(i.e., blunt) information relevant to threatening situations (Appendix M). The scale is
composed of four stressful situations (e.g., dentist appointment, hostage situation,
airplane ride during a steep dive, and the possibility of being laid off at work) followed
by eight statements that reflect different reactions in each situation. Each set of eight
statements is evenly divided into monitoring and blunting reactions. Coefficient alphas
for the monitoring scale range from .75 to.79 and .67 to .69 for the blunting scale (Miller,
1987). The coefficient alphas for the present study were .78 for the monitoring scale and
.62 for the blunting scale. Because the monitoring scale has been proven to be a better
predictor of health behaviors (Miller et al., 1988), only the monitoring scale was used in
subsequent analyses.
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Chapter Three
Results
Preliminary Analyses
Participants Who Opted for Prophylactic Mastectomy. Of the 192 women who
completed the on-line survey, 56 women (29%) reported having undergone prophylactic
mastectomies (see Figure 1). Of these women, 14 (25%) were found to be ineligible for
the following reasons: genetic testing done within the past year (n = 8), duplicate survey
entries (n = 3), report of both ovaries having been removed without a hysterectomy (n =
1), mastectomy prior to genetic testing (n = 1), and survey malfunction resulting in
missing data (n = 1). The mean age of the remaining 42 women was 36 years (SD = 8.07,
range = 19-55). The majority was Caucasian (93%), not of Ashkenazi Jewish heritage
(57%), married (71%), had a college degree or higher education (81%), and had an
annual household income greater than or equal to $40,000 (76%) (see Table 1). On
average, these women underwent prophylactic mastectomy 14 months prior to
participating in the study (M = 14.48; SD = 14.50) with time since prophylactic
mastectomy ranging for 0 to 58 months. The time that elapsed between genetic testing
and undergoing prophylactic mastectomy ranged from 1 month to 76 months (M = 18.69;
SD = 21.24).
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Figure 1. Flowchart of Recruitment

192 Surveys Received

136 NonProphylactic
Mastectomy
Surveys

56 Prophylactic
Mastectomy
Surveys

41 Ineligible Surveys

14 Ineligible Surveys

!31 Less than one year since
genetic testing

! 8 Less than one year since
genetic testing

! 7 Duplicate surveys

! 3 Duplicate surveys

! 2 Chemoprevention drugs

! 1 Survey malfunction

! 1 Ovaries removed w/o
hysterectomy

! 1 Ovaries removed w/o
hysterectomy
! 1 Mastectomy prior to
testing

95 Eligible
Non-Prophylactic
Mastectomy
Surveys

42 Eligible
Prophylactic
Mastectomy
Surveys
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Table 1
Demographic Characteristics of Participants Who Had Opted for Prophylactic
Mastectomy versus Participants Who Had Not Opted for Prophylactic Mastectomy
Participants who Opted for
Participants who Did Not Opt for
Prophylactic Mastectomy Prophylactic Mastectomy
N

(%)

N

(%)

Ashkenazi Jewish
Yes
No

18
24

(43%)
(57%)

27
68

39
3

(93%)
(7%)

93
2

30
12

(71%)
(29%)

55
40

8
34

(19%)
(81%)

20
75

(12%)
(76%)
(12%)

9
75
11

38

.91

.34

1.72

.18

.00

.97

.02

.89

(21%)
(79%)

Household Income
< $40, 000
5
32
> $40, 000
Did not answer 5

.14

(58%)
(42%)

Education
< Partial College
> College Grad

2.14

(98%)
(2%)

Marital Status
Married
Not Married

p

(28%)
(72%)

Race
White
Non-White

X2

(9%)
(79%)
(12%)

Participants Who Did Not Opt for Prophylactic Mastectomy. Of the 192 women
who completed on-line surveys, 136 women (71%) reported not having undergone
prophylactic mastectomies (see Figure 1). Of these women, 41 were found to be
ineligible for the following reasons: genetic testing done within the past year (n = 31),
duplicate survey entries (n = 7), use of chemoprevention drugs (n = 2), and report of both
ovaries having been removed without a hysterectomy (n = 1). The mean age of the
remaining 95 women was 35 years (SD = 8.84, range = 21-65). The majority was
Caucasian (98%), not of Ashkenazi Jewish heritage (72%), married (58%), had a college
degree or higher education (79%), and had an annual household income greater than or
equal to $40, 000 (79%) (see Table 1).
Women who did not opt for prophylactic mastectomy were asked about their
breast cancer surveillance behaviors. The majority of these women reported the
following breast cancer surveillance behaviors at least once in the past year: breast exam
conducted by a medical professional (96%), mammogram (78%), and MRI (61%) (see
Table 2). Regarding breast self-exams, 72% reported performing self-exams in the past
month with 64% reporting regular self-exams in the past year (“about one per month” or
“more than one per month”) (see Table 3). Eighty percent reported intentions to perform
regular self-exams in the upcoming year (“about one per month” or “more than one per
month”). Even with these high rates, only 23% of women expressed feeling either “very
confident” or “extremely confident” in personal performance of breast self-exams.
Twenty percent of these women reported plans (either “likely” or “extremely likely”) to
have a prophylactic mastectomy in the next 6 months (see Table 3).
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Table 2
Surveillance Behaviors of Participants Who Had Not Opted for Prophylactic Mastectomy
N

(%)

Breast Exam Conducted by Medical Professional in Past Year
Yes
No

91
4

(96%)
(4%)

Breast Exam Conducted by Medical Professional in Past Three Years
0
1
2
3
4

1
6
7
24
57

(1%)
(6%)
(8%)
(25%)
(60%)

74
21

(78%)
(22%)

16
14
20
33
12

(17%)
(15%)
(21%)
(35%)
(12%)

58
37

(61%)
(39%)

35
27
14
13
6

(37%)
(28%)
(15%)
(14%)
(6%)

Mammograms in Past Year
Yes
No
Mammograms in Past Three Years
0
1
2
3
4
MRI in Past Year
Yes
No
MRI in Past Three Years
0
1
2
3
4
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Table 3
Medical Characteristics of Participants Who Had Not Opted for Prophylactic
Mastectomy
N

(%)

Plan to have Prophylactic Mastectomy in the next 6 Months
Extremely Unlikely
Unlikely
Not Sure
Likely
Extremely Likely

52
13
11
8
11

(55%)
(13%)
(12%)
(8%)
(12%)

68
27

(72%)
(28%)

9
25
40
21

(10%)
(26%)
(42%)
(22%)

Self Breast Exam in Past Month
Yes
No
Self Breast Exam in Past Year
Not al all
Less than 1/month
About 1/month
More than 1/month

Intentions to perform Self Breast Exam in Next Year
Not al all
Less than 1/month
About 1/month
More than 1/month

6
13
56
20

(6%)
(14%)
(59%)
(21%)

Personal Confidence in Performing Self Breast Exam
Not at all
Little confident
Fairly confident
Very confident
Extremely confident

17
21
35
17
5

41

(18%)
(22%)
(37%)
(18%)
(5%)

T-tests or chi-square analyses were conducted, as appropriate, to compare the
participants who had opted for prophylactic mastectomy (n = 42) with the participants
who had not opted for prophylactic mastectomy (n = 95) on demographic variables. The
groups did not differ significantly on age (t = -.62, p = .53). On the demographic
variables of race, Ashkenazi Jewish heritage, marital status, education, and household
income, results revealed not even a marginally significant difference (p < .1) between the
groups (see Table 1). Therefore, none of these variables were included is covariates in
the subsequent analyses.
T-tests or chi-square analyses were also conducted to compare the groups on
medical variables. The groups did not differ significantly on menopausal status (!2 =
1.82, p = .18), body mass index (t = .17, p = .86), time since genetic testing (t = -.03, p =
.77), or whether or not they disclosed their positive genetic test results with their
physicians (!2 = .29, p = .59). Regarding family history of first degree relatives with
breast or ovarian cancers, the groups did not differ on whether or not they had first degree
relatives with breast cancer (!2 = .59, p = .44), but did differ significantly on whether or
not they had first degree relatives with ovarian cancer (!2 = 4.78, p = .03) (see Tables 4
and 5). Women in the prophylactic mastectomy group were less likely to have first
degree relatives with ovarian cancer.
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Table 4
Medical Characteristics of Participants Who Had Opted for Prophylactic Mastectomy
versus Participants Who Had Not Opted for Prophylactic Mastectomy
Participants who Opted for
Participants who Did Not Opt for
Prophylactic Mastectomy Prophylactic Mastectomy
M

(SD)

M

(SD)

Body Mass Index
24.42

(4.63)

24.57

(21.70)

32.16

43

p

.17

.86

-.03

.77

(5.0)

Time Since Genetic Testing (in months)
33.36

t

(21.81)

Table 5
Medical Characteristics of Participants Who Had Opted for Prophylactic Mastectomy
versus Participants Who Had Not Opted for Prophylactic Mastectomy
Participants who Opted for
Participants who Did Not Opt for
Prophylactic Mastectomy Prophylactic Mastectomy
N

(%)

N

(%)

Tell Physician Test Results
Yes
No

35
7

(83%)
(17%)

84
11

33
9

(79%)
(21%)

67
28

4
36
2

(9%)
(86%)
(5%)

27
65
3

(83%)
(17%)

88
7

44

.59

.59

.44

4.78

.03*

1.82

.18

(28%)
(69%)
(3%)

Menopausal Status
Premenopausal 35
Menopausal
7

.29

(71%)
(29%)

First Degree Relatives with Ovarian Cancer
Yes
No
Don’t Know

p

(88%)
(12%)

First Degree Relatives with Breast Cancer
Yes
No

X2

(93%)
(7%)

Relationship of Decision Making Variables to Choice of Risk-Reducing Option
The first hypothesis stated that the assessment of the pros and cons of
prophylactic mastectomy would be associated with the type of risk-reducing option
chosen. As predicted, more positive scores on the Decisional Balance Scale for
Prophylactic Mastectomy (pros-cons) (r = .31, p < .001) and higher scores on the pros
items alone (r = .29, p < .001) were significantly related to having undergone
prophylactic mastectomy surgery. Also as predicted, higher scores on the cons items
alone (r = -.25, p < .05) were significantly negative correlated with having undergone
prophylactic mastectomy surgery (see Tables 6 and 7).
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Table 6
Correlational Analyses of Decision Making and Perceived Impact Variables With Group
Status

Group Status
Decisional Balance Scale for Prophylactic Mastectomy
Pros
Cons
Total (Pros – Cons)
Cancer Worry Scale
Past Month
When Genetically Tested

.29**
- .25*
.31**
- .39***
.28**

Miller Behavioral Style Scale
Monitors
Blunter
Total Score (Monitors – Blunters)

.01
- .06
.04

Center for Epidemiologic Studies-Depression Scale

- .19*

Decisional Conflict Scale

- .38***

Decisional Regret Scale

- .58***

*
p < .05
** p< .001
*** p < .0001
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Table 7
Comparisons between Participants Who Had Opted for Prophylactic Mastectomy versus
Participants Who Had Not Opted for Prophylactic Mastectomy on Decision Making and
Perceived Impact Variables
Did Not Opt for PM
M

Opted for PM

(SD)

M

(SD)

t

p

Decisional Balance Scale for Prophylactic Mastectomy
Pros
Cons
Total (Pros – Cons)

12.99
13.27
-0.28

2.72
2.75
4.81

14.74
11.76
2.98

2.51
2.61
4.08

-3.55
3.01
-3.83

.0005**
.0031*
.0002**

7.61
10.37

2.78
3.57

5.19
12.50

2.45
2.78

4.87 <.0001***
-3.43 .0008**

10.06
4.98
5.08

3.35
2.63
4.35

10.14
4.64
5.50

3.38
2.71
4.69

-.13
.68
-.50

.8982
.4957
.6153

CES-D

12.02

10.15

8.10

7.51

2.52

.0133*

Decisional Conflict Scale

35.49

20.51

18.56

16.42 4.72

<.0001***

Decisional Regret Scale

29.63

17.17

6.07

10.96 9.65

<.0001***

Cancer Worry Scale
Past Month
When Genetically Tested
Miller Behavioral Style Scale
Monitors
Blunters
Total Score (M-B)

*
p < .05
** p< .001
*** p < .0001
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The second hypothesis stated that the treatment chosen would be related to
recommendation of that treatment by a physician. Specifically, if a physician had
recommended prophylactic mastectomy, women would have been more likely to have
chosen a prophylactic mastectomy. Of the 137 women surveyed, 91 reported receiving
at least one physician’s opinion about the risk-reducing option she should pursue.
Regarding the content of physician opinions, each group received an assortment of
physician opinions (see Table 8 and 9) ranging from one type of risk-reducing option
only (surveillance, prophylactic mastectomy, or chemoprevention) to a mixture of
opinions for all three options. Regarding recommendations for prophylactic mastectomy
only, 71% of the prophylactic mastectomy group received doctor recommendations that
included physician opinions only endorsing prophylactic mastectomy compared to 30%
of the no prophylactic mastectomy group. Twenty-nine percent of the prophylactic
mastectomy group and 70% of the no prophylactic group received opinions that included
options other than prophylactic mastectomy alone. These rates reflect a significant
relationship between physician opinions that only included prophylactic mastectomy and
risk-reducing option (prophylactic mastectomy versus no prophylactic mastectomy)
(Χ2 = 11.85; p < .001) (see Table 10). For the group as a whole, there was no relationship
between whether or not a woman received a physician opinion about the risk-reduction
option she should obtain and risk-reducing option (prophylactic mastectomy versus no
prophylactic mastectomy) (Χ2 = .00, p = 1.000) (see Table 11). However, the riskreducing groups did differ significantly on the number of doctor opinions received (t = 2.59, p = .01) (see Table 12) with women who underwent prophylactic mastectomy
receiving more doctor opinions.
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Table 8
Types of Doctor Recommendation for Women who Did Not Opt for Prophylactic
Mastectomy

Surveillance Only
Prophylactic Mastectomy Only
Chemoprevention Only
Mixed Recommendations

N

(%)

23
19
1
20

(36%)
(30%)
(2%)
(32%)

Table 9
Types of Doctor Recommendation for Women who Did Opt for Prophylactic Mastectomy

Surveillance Only
Prophylactic Mastectomy Only
Chemoprevention Only
Mixed Recommendations

N

(%)

0
20
0
8

(0%)
(71%)
(0%)
(29%)

Table 10
Correlational Analyses of Doctor Recommendations with Group Status
Participants who Opted for
Participants who Did Not Opt for
Prophylactic Mastectomy Prophylactic Mastectomy
N

(%)

N

(%)

Doctor Treatment Recommendations
PM Only
Mixed

20
8

(71%)
(29%)

19
44

49

(30%)
(70%)

X2

p

11.85

.0006

Table 11
Correlational Analyses of Whether or Not MD Opinion was Obtained With Group Status
Participants who Opted for
Participants who Did Not Opt for
Prophylactic Mastectomy Prophylactic Mastectomy
N

(%)

N

(%)

Ask MD Opinion
Yes
No

28
14

(67%)
(33%)

63
32

X2

p

.001

.00

(66%)
(34%)

Table 12
Comparison Between Participants Who Had Opted for Prophylactic Mastectomy versus
Participants Who Had Not Opted for Prophylactic Mastectomy on Number of MD
Opinions
Did Not Opt for PM
M

(SD)

Opted for PM
M

(SD)

Number of MD Opinions

t
-2.59

Prophylactic Mastectomy
No Prophylactic Mastectomy

2.82
2.30

p
.0111*

(.98)
(.84)

The third hypothesis stated that women with higher levels of cancer worry at time
of genetic testing would be more likely to have chosen prophylactic surgery than women
with lower levels of cancer worry. As predicted, women who retrospectively reported
higher cancer worry scores a month after receiving their BRCA1/2 positive results were
more likely to have chosen prophylactic mastectomy (r = .28, p < .001) (see Tables 6 and
7).
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The fourth hypothesis stated that information-seeking style would be related to
treatment choice with women with greater tendencies to use a monitoring informationseeking style more likely to have chosen prophylactic surgery. Contrary to predictions,
there was no significant relationship found between information monitoring (r = .01, p =
.8715) and risk-reduction option chosen.
Exploratory analyses were undertaken to examine relationships among the
variables found in the univariate analyses to be related to the risk-reducing option chosen.
Specifically, the first analysis sought to identify which retrospective variables from the
four decision making models provided the best fit for predicting risk-reducing choice in
BRCA1/2 positive, healthy, unaffected women. Because the dependent variable (riskreducing option) is dichotomous, a logistic regression analysis was performed using the
following significant (p < .05) retrospective variables for the entire sample: Decisional
Balance Scale for Prophylactic Mastectomy and Cancer Worry Scale from time of
genetic testing. Using the forward selection method, the Decisional Balance Scale for
Prophylactic Mastectomy was entered in first followed by the Cancer Worry score from
the time of genetic testing. The results (shown in Table 13) indicate that both measures
were significant in the multivariate analyses. Consistent with previous correlational
analyses, having a higher Decisional Balance Scale for Prophylactic Mastectomy total
score and higher retrospective Cancer Worry Scale score were associated with
membership in the prophylactic mastectomy group. Specifically, for every unit increase
on the Decisional Balance Scale for Prophylactic Mastectomy total score the likelihood
of being in the prophylactic mastectomy group increases by 21%. Similarly, for every
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unit increase on the retrospective Cancer Worry Scale the likelihood of being in the
prophylactic mastectomy group increases by 30%.

Table 13
Multivariate Logistic Regression Predicting Risk Reducing Option Group Membership
on Entire Sample
________________________________________________________________________
Variable
Decisional Balance Total Score
Cancer Worry Scale (at genetic testing)

OR
1.211
1.298

Note: OR = odds ratio; CI = confidence interval
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95% CI
1.10
1.13

1.33
1.49

p
<.0001
.0002

A second logistic regression analysis was conducted on only the 91 participants
who reported receiving advice on risk-reducing option from at least one physician. Again
in this case, the dichotomous dependent variable again was risk-reducing option. The
significant (p < .05), independent variables included the Decisional Balance Scale for
Prophylactic Mastectomy, the Cancer Worry Scale from time of genetic testing, and
treatment recommendation of prophylactic mastectomy exclusively. Using the forward
selection method, the treatment recommendation of prophylactic mastectomy only was
entered in first followed by the Cancer Worry score from the time of genetic testing. The
Decisional Balance Scale for Prophylactic Mastectomy was not included in this model, as
it did not meet the .05 significance level. The results (shown in Table 14) indicate the
two measures that were significant in multivariate analyses. Having a physician
recommendation for prophylactic mastectomy exclusively and higher Cancer Worry
Scale scores at time of genetic testing were associated with membership in the
prophylactic mastectomy group. Specifically, having a doctor recommend prophylactic
mastectomy exclusively increases the likelihood of being in the prophylactic mastectomy
group by 625%. Likewise, for every unit increase on the retrospective Cancer Worry
Scale score the likelihood of being in the prophylactic mastectomy group increases by
27%. A possible explanation for the exclusion of the Decisional Balance Scale for
Prophylactic Mastectomy in this model is that it is significantly correlated with treatment
recommendations of prophylactic mastectomy variable are significantly correlated
(r = -.38, p < .001).
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Table 14
Multivariate Logistic Regression Predicting Risk Reducing Option Group Membership
the Subsample Who Reported Seeking Advice on Risk-Reducing Options from at Least
One Physician
________________________________________________________________________
Variable
Treatment Recommendation of PM only
Cancer Worry Scale (at genetic testing)

OR
6.255
1.266

95% CI
2.20
1.06

17.76
1.51

p
.0006
.0081

Note: OR = odds ratio; CI = confidence interval
Relationship of Perceived Impact Variables to Choice of Risk-Reducing Option
A final set of analyses tested hypotheses that women who chose prophylactic
mastectomy would experience less decisional conflict, less decisional regret, lower levels
of depressive symptomatology, and lower levels of current cancer worry than women
who did not choose prophylactic mastectomy. As predicted, scores on the Decisional
Conflict Scale, Decisional Regret Scale, CES-D and Cancer Worry Scale were all
negatively correlated with risk-reducing option. The direction of these relationships
indicates that, as expected, having chosen prophylactic mastectomy was associated with
less decisional conflict (r = -.38, p < .0001), decisional regret (r = -.58, p < .0001),
depressive symptomatology (r = -.19, p < .05), and cancer worry (r = -.39, p < .0001)
(see Tables 6 and 7).
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Chapter Four
Discussion
The primary goal of the present study was to explore the relationship between a
set of theory-driven decision making variables and the actual treatment decisions made
by a group of healthy, unaffected women who had tested positive for a BRCA1/2 gene
mutation. In addition, the perceived impact (conflict, regret, depressive symptomatology,
and current cancer worry) of the treatment option selected was explored. This discussion
will review the findings, consider the limitations of the current study, and identify future
research directions.
Consistent with predictions, the choice of risk-reducing option (prophylactic
mastectomy versus no prophylactic mastectomy) was associated with the following
decision making variables: assessment of advantages and disadvantages of risk reducing
strategies, physician input, and past cancer worry. Like in the normative decision making
theory (Schwartz, Peshkin, et al., 2005; Armstrong et al., 2000; Lerman et al., 1996),
women who rated the advantages of prophylactic mastectomy higher were more likely to
have obtained a prophylactic mastectomy while women who had rated the disadvantages
of prophylactic mastectomy as higher were less likely to obtain a prophylactic
mastectomy. As in the shared decision making theory (McNutt, 2004; Coulter, 2002),
physician recommendations for prophylactic mastectomy only are significantly related to
risk-reducing option (prophylactic mastectomy versus no prophylactic mastectomy) with
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significantly more women from the prophylactic mastectomy group having received
recommendations for prophylactic mastectomy only. As suggested in affect based theory
(Slovic, Finucane, Peter, & MacGregor, 2004; Ubel & Lowenstein, 1997; Schwartz,
Peshkin, et al., 2005), women who retrospectively reported higher levels of cancer worry
at time of genetic testing were more likely to have undergone prophylactic mastectomy.
Finally, contrary to predictions based in previous research on information-seeking style
(Miller, Roussi, Caputo, & Kruss, 1995), no relationship existed between monitoring
information-seeking style and risk-reduction option.
The predictive values of the significant, retrospective independent variables were
looked at in two separate logistic regression models. When the Decisional Balance Scale
for Prophylactic Mastectomy and Cancer Worry Scale from time of genetic testing were
included in the model they both contributed significantly to the chances of a women
choosing prophylactic mastectomy in the entire sample. In order to investigate the
physician input variable, another logistic regression model was run only using the sample
that had reported receiving an opinion on which risk-reducing option to undergo from at
least one physician. In this model, only the physician recommendation and Cancer
Worry Scale from the time of genetic testing were found to contribute significantly to a
women choosing prophylactic mastectomy.
Finally, all the perceived impact variables (the Decisional Conflict Scale,
Decisional Regret Scale, CES-D, and Cancer Worry Scale) were found to be negatively
correlated with risk-reducing option. As expected, women who opted for prophylactic
mastectomy reported less decisional conflict, regret, depressive symptomatology, and
cancer worry.
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These findings expand the current decision making information literature with
BRCA1/2 gene mutation carriers in three ways. The first way involves the sample
studied. Past research has been conducted only on heterogeneous samples of women
(e.g., affected and unaffected, BRCA1/2 gene mutation carriers, and various definitions of
women at high risk) (Van Dijk et al., 2003; Stefanek et al., 1999; Armstrong et al., 2000).
This study focuses only on women without a personal history of cancer who have tested
positive for the BRCA1/2 gene mutation. Therefore, all these women have the elevated
chances of being diagnosed with breast and/or ovarian cancers in their lifetimes. The
second way this study extends the literature on decision making and BRCA1/2 is to
investigate variables related to the decision of whether or not to opt for prophylactic
mastectomy. Although genetic testing decisions and prophylactic oophorectomy
decisions have been studied previously, few studies have looked at decisions surrounding
prophylactic mastectomy (Tercyak et al., 2007). Finally, this study examined variables
from four different decision making theories. Previous research in this area has generally
been more limited in scope.
As noted in previous research on normative decision making, women who ranked
the advantages of either genetic testing (Armstrong et al., 2000; Lerman et al., 1996) or
prophylactic oophorectomy (Fry, Rush, Busby-Earle, & Cull, 2001) higher than the
disadvantages were more likely to pursue these options. Similar to this previous
research, this study found that women who rated the advantages of prophylactic
mastectomy higher than the disadvantages of prophylactic mastectomy were more likely
to pursue prophylactic mastectomy. This study is novel in that it investigates the
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normative decision making theory in relation to whether or not BRCA1/2 gene mutations
carriers without a history of cancer opt for prophylactic mastectomy.
The shared decision making, or physician input, literature on genetic testing and
treatment outcome suggests that physician’s opinions were both desired (Armstrong et
al., 2002) and a contributing factor in whether or not women pursued genetic testing
(Schartz, Lerman, et al., 2005). Likewise in this study, treatment recommendation for
prophylactic mastectomy was significantly related to choice of prophylactic mastectomy
in the women who sought out the opinion of one or more physicians.
Previous research with the affect-based decision making theory suggests that
higher cancer-related distress and worry lead women to pursue genetic testing (Lerman et
al., 1997) and report higher intentions for prophylactic surgery (Van Dijk et al., 2003;
Stefanek et al, 1999). This research is similar to these studies. Women who reported
higher cancer worry at the time of genetic testing were more likely to obtain prophylactic
mastectomies.
Prior research on genetic counseling decisions and information-seeking style
suggested that monitors are more likely to amplify the negative impact of testing (Lerman
et al., 1994) and perceived risk (Sherman et al., 1995). Extrapolating from these findings,
we hypothesized that high monitoring BRCA1/2 genetic mutation carriers would amplify
the negatives of their situation and amplify their risks thereby resulting in more
prophylactic mastectomy decisions. Unlike the previous research on information-seeking
style, greater use of a monitoring coping style was not related to risk-reducing option
choice. This discrepancy may have something to do with the women sampled. Women
who frequent the FORCE website are likely to be actively seeking out information on
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their BRCA1/2 status (i.e., monitoring). Therefore, women with blunting coping styles
may have been less likely to have accessed the study through this information-based
website.
Previous research has examined the relationship of BRCA1/2 gene mutation status
to quality of life and psychological distress. Tercyak et al. (2007) report on the quality of
life and psychological distress of a sample of breast cancer patients with either positive
results (15%) or uninformative results (85%). Whether or not women chose to undergo
contralateral prophylactic mastectomy (versus unilateral mastectomy or lumpectomy) did
not predict short-term quality of life or cancer-specific distress. In a study most similar to
the present study, Madalinkska et al. (2005) compare high-risk women who opt for
periodic gynecologic screening versus prophylactic bilateral salpingo-oophorectomy.
While no significant differences were found in generic quality of life, the group opting
for prophylactic oophorectomy did report significantly less worries specific to breast and
ovarian cancers and lower cancer risk perceptions. These results are similar to findings
from the present study which suggest that women who chose prophylactic mastectomy
are actually doing better psychologically in terms of experiencing lower levels of current
cancer worry and depressive symptomatology than women who did not opt for
prophylactic mastectomy. Besides a measure of general quality of life (e.g., depressive
symptomatology) and cancer specific worry, the present study includes variables of
decisional conflict and decisional regret. This is similar to finding for decisional regret
(Borgen et al., 1998) in which the majority of women (n = 349) who signed up for the
National Prophylactic Mastectomy Registry between 1945 and 1996 did not express
regret over their decision to undergo prophylactic mastectomy. Likewise, in a small
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study (N = 14) on decisional satisfaction (Stefanek, Helzlsouer, Wilcox, & Houn, 1995)
with women at high risk, satisfaction with prophylactic mastectomy was high for all
participants. Therefore this study expands the psychological variables studied and
focuses exclusively on a positive BRCA1/2 sample.
Limitations
This study had several limitations. Without a valid and reliable measure of the
perceived advantages and disadvantages of undergoing prophylactic mastectomy
available in the literature, the Decisional Balance Scale for Prophylactic Mastectomy was
specifically designed for this study. This measure was developed by taking items on the
assessment of advantages and disadvantages of prophylactic mastectomy by women at
increased risk for breast cancer from the literature (Claes, et al., 2005). Coefficient
alphas calculated in the study were weak (.48 for the advantages scale and .44 for the
disadvantages scale), suggesting the findings involving this measure be cautiously
considered.
The physician input variables possessed a number of weaknesses.

These

variables included whether or not a physician gave his/her opinion regarding riskreducing strategy, how many different physician opinions were obtained, and the specific
nature of the recommendations. While 42 women in this sample underwent prophylactic
mastectomies, only 28 women reported receiving a physician’s opinion regarding riskreducing strategies. However, all 42 women had to have worked with surgeons willing to
perform their prophylactic mastectomies. Assuming they did not undergo prophylactic
mastectomy against medical advice, all 42 women of these women had in a sense
received opinions from at least one doctor regarding risk-reducing strategies.
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Because of the cost of gene mutation testing (Peterson, Milliron, Lewis, Goold, &
Merajver, 2002), the profile of FORCE members, and the need to have Internet access, it
was no surprise that the sample for the current study was made up primarily of
Caucasian, well-educated, higher income women. This feature limits the generalizability
of these findings to populations more diverse with regard to race/ethnicity, education, and
socioeconomic status.
In order to attain a sample of positive, unaffected women of this size, an
anonymous web-based survey was necessary. This method of data collection has
drawbacks in regards to limited access and limited tracking ability. As stated above, only
women who had access to the Internet were able to participate. In addition, there was no
way to track the response rate to determine if a systematic bias existed connected with
whether or not a woman agreed to participate. Finally, based on same birthdates and
similar demographic data, ten women were found to have completed the survey more
than once.
Limitations of this study also exist because of the retrospective, self-report, crosssectional nature of this study. Three of the measures (Decisional Balance Scale for
Prophylactic Mastectomy, Cancer Worry Scale at time of genetic testing, and the
Decisional Conflict Scale) asked respondents to provide retrospective information.
Although care was taken in the instructions to provide context by cueing participants to
both the season of the year and major events that coincided with their genetic testing, the
accuracy of the recalled responses is impossible to verify. In addition, all data were
collected via self-report without any means to verify that all eligibility criteria had been
met or the accuracy of the medical information provided, including recommendations for
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risk reduction. Ideally, corroborating medical data would also have been collected from
medical care providers. Finally, the cross-sectional design limits the ability to make
conclusions about the causal relationships between the decision making variables and the
risk-reducing options chosen.
Future Directions
The research designs of future studies could be improved in several ways. More
information about decision making variables for risk-reducing options could be obtained
by designing prospective studies including pre-genetic testing baseline assessments.
Therefore, differences between individuals prior to testing could be identified. In
addition, a longitudinal research design would allow for a better understanding of the
variables that go into risk-reducing decisions, as well as the impact of these risk-reducing
decisions over time. Because women with the BRCA1/2 gene mutation are at increased
risk for both breast and ovarian cancers (Antoniou et al., 2003), future research should
broaden the scope of risk-reducing options studied in these healthy, unaffected BRCA1/2
gene mutation carriers. In contrast to the present study that focused only on the decision
to undergo prophylactic mastectomy, future research should include decision making
variables for prophylactic oophorectomy, as well as chemoprevention as the use of this
option increases.
Data from this study suggest women who do not opt to undergo prophylactic
mastectomy are experiencing higher levels of cancer worry, decisional conflict,
decisional regret, and depressive symptomatology when compared to the women who do
undergo prophylactic mastectomies. In order for healthy, unaffected, gene mutation
carriers to make informed risk-reducing decisions, information on the psychological
62

distress of not opting for prophylactic mastectomy needs to be available. No studies of
this kind could be found in the current literature. Future research should focus on the
degree of distress experienced by this sample of healthy, unaffected, gene mutation
carriers who do not opt for prophylactic mastectomy, along with the best ways to provide
psychological services if and when necessary.
The current study includes only women who received a positive genetic test
results. However, a woman may receive ambiguous (i.e., indeterminate) BRCA1/2 test
results. In these cases, the test may show a BRCA1/2 mutation that has yet to be
correlated with breast or ovarian cancers. Because women tested for the BRCA1/2 gene
mutation may receive ambiguous results, ultimately more future research should include
large enough samples of women who have received indeterminate results in order to
establish if and how their decision making differs from women who receive positive test
results. Finally, all future studies should strive to recruit larger, more demographically
diverse samples in order to generalize study findings.
Summary
This study addresses a salient issue that BRCA1/2 gene mutation carriers face.
Prior to this study, little was known about the decision making factors underlying the
choice of prophylactic mastectomy for women with a BRCA1/2 mutation. One hundred
thirty-seven unaffected, positive gene mutation carriers were assessed via an on-line
survey on the following theory-based decision making variables: advantages and
disadvantages of prophylactic mastectomy (normative decision theory), physician
recommendation (shared decision making theory), cancer worry (affect theory), and
information-seeking coping style. The results suggest higher assessments of advantages
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over disadvantages of prophylactic mastectomy, likelihood of doctor recommendation for
prophylactic mastectomy exclusively, and higher cancer worry at time of testing are
associated with choosing the risk-reducing option of prophylactic mastectomy.
Additional findings suggested that women who chose prophylactic mastectomy fared
better psychologically than those who did not in terms of experiencing less decisional
conflict and regret as well as lower levels of cancer worry and depressive
symptomatology. Continued research addressing decision making variables and the
impact of risk-reducing decisions may lead to improved understanding and interventions
on how best to approach these difficult decisions.

64

References
Antoniou, A., Pharoah, P.D., Narod, S., Risch, H.A., Eyfjord, J.E., & Hopper, J.L.
(2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2
mutations detected in cases unselected for family history: A combined analysis of 22
studies. American Journal of Human Genetics, 72, 1117-1130.
Armstrong, K., Calzone, K., Stopfer, J., Fitzgerald, G., Coyne, J., & Weber, B. (2000).
Factors associated with decisions about clinical BRCA1/2 testing. Cancer
Epidemiology, Biomarkers, & Prevention, 9, 1251-1254.
Armstrong, K., Stopfer, J., Calzone, K., Fitzgerald, G., Coyne, J., & Weber, B. (2002).
What does my doctor think? Preferences for knowing the doctor’s opinion among
women considering clinical testing for BRCA1/2 mutations. Genetic Testing, 6, 115118.
Baum, A., Friedman, A.L., & Zakowski, S.G. (1997). Stress and genetic testing for
disease risk. Health Psychology, 16, 8-19.
Bluman, L.G., Rimer, B.K., Berry, D.A., Borstelmann, N., Iglehart, D., Regan, K., et al.
(1999). Attitudes, knowledge, and risk perceptions of women with breast and/or
ovarian cancer considering testing for BRCA1 and BRCA2. Journal of Clinical
Oncology, 17, 1040-1046.
Borgen, P.I., Hill, A.D.K., Tran, K.N., Van Zee, K.J., Massie, M.J., Payne, D., et al.
(1998). Patient regrets after bilateral prophylactic mastectomy. Annals of Surgical
Oncology, 5, 603-606.
Botkin, J.R., Smith, K.R., Croyle, R.T., Baty, B.J., Wylie, J.E., Dutson, D., et al. (2003).
Genetic testing for a BRCA1 mutation: Prophylactic surgery and screening behavior
in women 2 years post testing. American Journal of Medical Genetics, 118A, 201209.
Bowen, D. J., Helmes, A., Powers, Anderson, M.R., Burke, W., McTiernan, A., & Durfy,
S. (2003). Predicting breast cancer screening intentions and behavior with emotion
and cognition. Journal of Social and Clinical Psychology, 22(2), 213-232.
Brehaut, J.C., O’Connor, A.M., Wood, T.J., Hack, T.F., Siminoff, L., Gordon, E., et al.
(2003). Validation of a decision regret scale. Medical Decision Making, 23, 281292.
65

Brekelmans, C.T.M., Seynaeve, C., Bartels, C.C.M., Tilanus-Linthorst, M.M.A., MeijersHerjboer, E.J., Crepin, C.M.G., et al. (2001). Effectiveness of breast cancer
surveillance in BRCA1/2 gene mutation carriers and women with high familial risk.
Journal of Clinical Oncology, 19, 924-930.
Calderon-Margalit, R., & Paltiel, O. (2004). Prevention of breast cancer in women who
carry BRCA1 or BRCA2 mutations: A critical review of the literature. International
Journal of Cancer, 112, 357-364.
Centers for Disease Control and Prevention. (1999). Question appraisal system: QAS99. Retrieved August 30, 2006, from
http://appliedresearch.cancer.gov/areas/cognitive/qas99.pdf#search=%22qas%2099%
22
Chaliki, H., Loader, S., Levenkron, J.C., Logan-Young, W., Hall, W.J., & Rowley, P.T.
(1995). Women’s receptivity to testing for a genetic susceptibility to breast cancer.
American Journal of Public Health, 85, 1133-1135.
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.).
Hillsdale, NJ: Lawrence Erlbaum.
Connolly, T., & Reb, J. (2005). Regret in cancer-related distress. Health Psychology,
24, S29-S34.
Coulter, A. (2002). Whatever happened to shared decision-making? Health
Expectations, 5, 185-186.
Devins, G.M., Orme, C.M., Costello, C.G., and Binik, Y.M. (1998). Measuring
depressive symptoms in illness populations: Psychometric properties in illness
populations: Psychometric properties of the Center for Epidemiologic Studies
Depression (CES-D) Scale. Psychology and Health, 2 (2), 139-156.
Early Breast Cancer Trialists’ Collaborative Group. (1998). Tamoxifen for early breast
cancer: An overview of the randomized trials. Lancet, 351, 1451-1467.
Eisen, A. (1999). Prophylactic mastectomy—The price of fear. New England Journal of
Medicine, 340, 137-138.
Facing our Risk of Cancer Empowered, Inc. (FORCE). http://www.facingourrisk.org
Fentiman, I.S. (1998). Psychological sequelae of screening women with a family history
of breast cancer. European Journal of Cancer, 34, 1991-1992.

66

Feunteun, J., Narod, S.A., Lynch, H.T., Watson, P., Conway, T., Lynch, J., et al. (1993).
A breast-ovarian cancer susceptibility gene maps to chromosome 17q21. American
Journal of Human Genetics, 52, 736-742.
Fisher, B., & Redmond, C. (1991). New perspective on cancer of the contralateral
breast: A marker for assessing tamoxifen as a preventive agent. Journal of the
National Cancer Institute, 83, 1278-1280.
Fisher, B., Costantino, J.P., Wickerhams, D.L., Redmond, C.K., Kavanah, M., Cronin,
W.M., et al. (1998). Tamoxifen for prevention of breast cancer: Report of the
National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the
National Cancer Institute, 90, 1371-1388.
Fry, A., Rush, R., Busby-Earle, C., & Cull, A. (2001). Deciding about prophylactic
oophorectomy: What is important to women at increased risk of ovarian cancer?
Preventive Medicine, 33, 578-585.
Geller, B.A., Bernhardt, T., Doksum, K.J., Helzlsouer, P., Wilcox, N.A., & Holtzman,
N.A. (1998). Decision-making about breast cancer susceptibility testing: How
similar are the attitudes of physicians, nurse practitioners, and at-risk women?
Journal of Clinical Oncology, 16, 2868-2876.
Gilbert, F.J., Cordiner, C.M., Affleck, I.R., Hood, D.B., Mathieson, D., & Walker, L.G.
(1998). Breast screening: The psychological sequelae of false-positive recall in
women with and without a family history of breast cancer. European Journal of
Cancer, 34, 2010-2014.
Hann, D., Winter, K., and Jacobsen, P. (1999). Measurement of depressive symptoms
in cancer patients: Evaluation of the CES-D. Journal of Psychosomatic Research, 46
(5), 437-443.
Hartmann, L.C., Schaid, D.J., Woods, J.E., Crotty, T.P., Myers, J.L., Arnold, P.G., et al.
(1999). Efficacy of bilateral prophylactic mastectomy in women with a family
history of breast cancer. The New England Journal of Medicine, 340, 77-84.
Hartmann, L.C., Sellers, T.A., Schaid, D.J., Frank, T.S., Soderberg, C.L., Sitta, D.L., et
al. (2001). Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2
gene mutation carriers. Journal of the National Cancer Institute, 93, 1633-1637.
Horowitz, M., Wilner, N., & Alvarez, W. (1979) Impact of Event Scale: A measure of
subjective stress. Psychosomatic Medicine, 41, 209-218.

67

Hurley, K.E., Miller, S.M., Costalas, J.W., Gillespie, D., & Daly, M.B. (2001).
Anxiety/uncertainty reduction as a motivation for interest in prophylactic
oophorectomy in women with a family history of ovarian cancer. Journal of
Women’s Health & Gender-Based Medicine, 10,189-199.
Jacobsen, P.B., Valdimarsdottir, H.B., Brown, K.L., & Offit, K. (1997). Decisionmaking about genetic testing among women at familial risk for breast cancer.
Psychosomatic Medicine, 59, 459-466.
King, M-C, Wieand, S., Hale, K., Lee, M., Walsh, T., Owens, K., et al. (2001).
Tamoxifen and breast cancer incidence among women with inherited mutations in
BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABPP1) Breast Cancer Prevention Trial. Journal of the American Medical Association,
286, 2251-2256.
Klaren, H.M., van’t Veer, L.J., van Leeuwen, F.E., & Rookus, M.A., (2003). Potential
for bias in studies of efficacy of prophylactic surgery for BRCA1 and BRCA2
mutation. Journal of National Institute, 95, 941-947.
Kuhl, C.K., Schmutzler, R.K., Leutner, C.C., Kempe, A., Wardelmann, E., Hocke, A., et
al. (2000). Breast MR imaging screening in 192 women proved or suspected to be
carriers of a breast cancer susceptibility gene: Preliminary results. Radiology, 215,
267-279.
Kuhl, C.K., Schrading, S., Leutner, C.C., Morakkabati-Spitz, N., Wardelmann, E.,
Fimmers, R., et al. (2005). Mammography, breast ultrasound, and magnetic
resonance imaging for surveillance of women at high familial risk for breast cancer.
Journal of Clinical Oncology, 33, 8469-8476.
Lampic, C., Thurfjell, E., Bergh, J. & Sjödén, P.O. (2001). Short-term and long-term
anxiety and depression in women recalled after breast cancer screening. European
Journal of Cancer, 37, 463-469.
Lerman, C., Biesecker, B., Benkendorf, J.L., Kerner, J., Gomez-Caminero, A., Huges, C.,
et al. (1997). Controlled trial of pretest education approaches to enhance informed
decision-making for BRCA1 gene testing. Journal of the National Cancer Institute,
89, 148-157.
Lerman, C., Daly, M., Masny, A., & Balshem, A. (1994). Attitudes about genetic testing
for breast-ovarian susceptibility. Journal of Clinical Oncology, 12, 843-850.
Lerman, C., Hughes, C., Croyle, R.T., Main, D., Durham, C., Snyder, C., et al. (2000).
Prophylactic surgery decisions and surveillance practices one year following
BRCA1/2 testing. Preventive Medicine, 31, 75-80.
68

Lerman, C., Kash, K., & Stefanek, M. (1994). Younger women at increased risk for
breast cancer: Perceived risk, psychological well-being, and surveillance
behavior. Journal of the National Cancer Institute Monographs, 16, 171-176.
Lerman, C., Narod, S., Schulman, K. Hughes, C., Gomez-Caminero, A., Bonney, G., et
al. (1996). BRCA1 testing in families with hereditary breast-ovarian cancer : A
prospective study of patient decision making and outcomes. Journal of American
Medical Association, 275, 1885-1892.
Lerman, C., Trock, B., Rimer, B.K., Jepson, C., Brody, D., & Boyce, A. (1991).
Psychological side effects of breast cancer screening. Health Psychology, 10, 259267.
Lostumbo, L., Carbine, N., Wallace, J., & Ezzo, J. (2005). Prophylactic mastectomy for
the prevention of breast cancer. The Cochrane Collaboration, 3, no page numbers.
Lowe, J.B., Balanda, K.P., Del Mar, C., & Hawes, E. (1999). Psychologic distress in
women with abnormal findings in mass mammography screening. Cancer, 85, 11141118.
Madalinska, J.B., Hollenstein, J., Bleiker, E., van Beurden, M., Valdimarsdottir, H.B.,
massuger, L.F., Gaarenstroom, K.N., Mourits, M.J.E., Verheijen, R.H.M., van Dorst,
E.B.L., van der Putten, H., van der Velden, K., Boonstra, H., & Aaronson, N.K.
(2005). Quality-of-life effects of prophylactic salpingo-oophorectomy versus
gynecologic screening among women at increased risk of hereditary ovarian cancer.
Journal of Clinical Oncology, 23, 6890- 6898.
Marchetti, P., Di Rocco, C.Z., Ricevuto, E., Bisenga, R., Cianci, G., Calista, F., et al.
(2004). Reducing breast cancer incidence in familial breast cancer: Overlooking the
present panorama. Annals of Oncology, 15 (Supplement 1), 127-134.
McNutt, R.A. (2004). Shared medical decision making: Problems, process, and
progress. Journal of the American Medical Association, 292, 2516-2518.
Matloff, E.T., Shappell, H., Brierley, K., Bernhardt, B.A., McKinnon, W., & Peshkin,
B.N. (2000). What would you do? Specialists’ perspectives on cancer genetic
testing, prophylactic surgery, and insurance discrimination. Journal of Clinical
Oncology, 18, 2484-2492.
Meijers-Heijboer, E.J., Verhoog, L.C., Brekelmans, C.T.M., Seynaeve, C., TilanusLinthorst, M.M.A., Wagner, A., et al. (2000). Presymptomatic DNA testing and
prophylactic surgery in families with a BRCA1 or BRCA2 mutation. The Lancet, 355,
2015-2020.

69

Meijers-Herjboer, E.J., Verhoog, L.C., Brekelmans, C.T.M., Tilanus-Linthorst, M.M.A.,
Wagner, A., Dukel, L., et al. (2000). Presymptomatic DNA testing and prophylactic
surgery in families with a BRCA1 or BRCA2 mutation. The Lancet, 355, 2015-2020.
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P.A., Harshman, K., & Tavtigian, S.
(1994). A strong candidate for the breast and ovarian susceptibility gene BRCA1.
Science, 266, 66-71.
Miller, S.M. (1987). Monitoring and blunting: Validation of a questionnaire to assess
styles of information seeking under threat. Journal of Personality and Social
Psychology, 52, 345-353.
Miller, S.M., Roussi, P., Caputo, G.C., & Kruus, L. (1995). Patterns of children’s
coping with an aversive dental treatment. Health Psychology, 14, 236-246.
National Institutes of Health Consensus Development Panel. (2001). National Institutes
of Health Consensus Development Conference Statement: Adjuvant therapy for
breast cancer, November 1-3, 2000. Journal of National Cancer Institute, 93, 979989.
O’Connor, A. (1995). Validation of a decisional conflict scale. Medical Decision
Making, 15, 25-30.
O’Connor, A.M., Tugwell, P., Wells, G.A., et al. (1998). A decision aid for women
considering hormone therapy after menopause: Decision support framework and
evaluation. Patient Education and Counseling, 33, 267-279.
O'Malley M.S., Klabunde, C.N., McKinley, E.D., & Newman, B. (1997). Should we test
women for inherited susceptibility to breast cancer? What do NC primary care
physicians think. North Carolina Medical Journal, 58, 176-180.
Pasacreta, J. V. (2003). Psychosocial issues associated with genetic testing for breast
and ovarian cancer risk: An integrative review. Cancer Investigation, 21, 588-623.
Peskin, B.N., DeMarco, T.A., Brogan, B.M., Lerman, C., & Isaacs, C. (2001). BRCA1/2
testing: Complex themes in result interpretation. Journal of Clinical Oncology, 19,
2555-2565.
Peskin, B.N., Isaacs, C., Finch, C., Kent, S., & Schwartz, M.D. (2003). Tamoxifen as
chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: A pilot
survey of physicians. Journal of Clinical Oncology, 21, 4322-4328.
Peshkin, B.N., Schwartz, M.D., Isaacs, D., Hughes, C., Main, D., & Lerman, C. (2002).
Utilization of breast cancer screening in a clinically based sample of women after
BRCA1/2 testing. CancerEpidemiology, Biomarkers, and Prevention, 11, 1115-1118.
70

Radloff, L.S. (1977). The CES-D Scale: A self-report depression scale for research in
the general population. Applied Psychological Measurement, 1 (3), 385-401.
Rebbeck, T.R., Friebel, T., Lynch, H.T., Neuhausen, S.L., van’t Veer, L., Garber, J.E., et
al. (2004). Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1/2
mutation carriers: The PROSE study group. Journal of Clinical Oncology, 22, 10551062.
Rees, G., Fry, A., Cull, A., & Sutton, S. (2004). Illness perceptions and distress in
women at increased risk of breast cancer. Psychology and Health, 19, 749-765.
Robles-Diaz, L., Goldfrank, D.J., Kauff, N.D., Robson, M., & Offitt, K. (2004).
Hereditary ovarian cancer in Ashkenazi Jews. Familial Cancer, 3, 259-264.
Robson, M.E., & Offit, K. (2004). Breast MRI for women with hereditary cancer risk.
Journal of American Medicine, 292, 1368 –1370.
Rubin, S.C. (2003). BRCA-related ovarian cancer. Cancer, 97, 2127-2129.
Rutqvist, L.E., Cedermark, B., Glas, U., Mattsson, A., Skoog, L., Somell, A., et al.
(1991). Contralateral primary tumors in breast cancer patients in a randomized trial
of adjuvant tamoxifen therapy. Journal of the National Cancer Institute, 83, 12991306.
Schwartz, M.D., Lerman, C., Miller, S.M., Daly, M., & Masny, A. (1995). Coping
disposition, perceived risk, and psychological distress among women at increased risk
for ovarian cancer. Health Psychology, 14, 232-235.
Schwartz, M.D., Lerman, C., Brogan, B., Peshkin, B.N., Isaacs, C., DeMarco, T., et al.
(2005). Utilization of BRCA1/2 mutation testing in newly diagnosed breast cancer
patients. Cancer Epidemiology, Biomarkers, & Prevention, 14, 1003-1007.
Schwartz, M.D., Peshkin, B.N., Tercyak, K.P., Taylor, K.L., & Valdimarsdottir, H.
(2005). Decision-making and decision support for hereditary breast-ovarian cancer
susceptibility. Health Psychology, 24, S78-S84.
Slovic, P., Finucane, M.L., Peters, E., & MacGregor, D.G. (2004). Risk as analysis and
risk as feelings: Some thoughts about affect, reason, risk, and rationality. Risk
Analysis, 24, 311-322.
Smith, R.A., Saslow, D., Sawyer, K.A., Burke, W., Costanza, M.E., Evans, W.P., et al.
(2003). American Cancer Society Guidelines for Breast Cancer Screening: Update
2003. CA: A Cancer Journal for Clinicians, 53, 141-169.

71

Song, M-K & Sereika, S.M. (2006). An evaluation of the Decisional Conflict Scale for
measuring the quality of end-of-life decision making. Patient Education and
Counseling, 61, 397-404.
Spielberger, C.D. (1983). Manual for the State-Trait Anxiety Inventory: STAI (Form
Y). Palo Alto, CA: Consulting Psychologists Press.
Stefanek, M.E. (1995). Bilateral prophylactic mastectomy: Issues and concerns.
Journal of National Cancer Institute Monogr, 17, 37-42.
Stefanek, M., Enger, C., Benkendorf, M.S., Flamm Hogg, S., & Lerman, C. (1999).
Bilateral prohylactic mastectomy decision making: A vignette study. Preventive
Medicine, 29, 216-221.
Stefanek, M.E., Helzlsouer, K.J., Wilcox, P.M., & Houn, F. (1995). Predictors of and
satisfaction with bilateral prophylactic mastectomy. Preventative Medicine, 24, 412419.
Steggles, S., Lightfoot, N., & Sellick, S.M. (1998). Psychological distress associated
with organized breast cancer screening. Cancer Prevention and Control, 2, 213-220.
Stoutjesdijk, M.J., Boetes, C., Jager, G.J., Beex, L., Bult, P., Hendriks, J.H., et al. (2001).
Magnetic resonance imaging and mammography in women with a hereditary risk of
breast cancer. Journal of the National Cancer Institute, 93, 1095-1102.
Struewing, J.P., Lerman, C., Kase, R.G., Giambaressi, T.R., & Tucker, M.A. (1995).
Anticipated uptake and impact of genetic testing on hereditary breast and ovarian
cancer families. Cancer Epidemiological Biomarkers and Prevention, 4, 169-173.
Tercyak, K.P., Peshkin, B.N., Brogan, B.M., DeMarco, T., Pennanen, M.F., Willey, S.C.,
Magnant, C.M., Rogers, S., Isaacs, C., & Schwartz, M.D. (2007). Quality of life
after contralateral prophylactic mastectomy in newly diagnosed high-risk breast
cancer patients who underwent BRCA1/2 genetic testing. Journal of Clinical
Oncology, 25, 285-291.
Tilanus-Linthorst, M.M. A., Obdeijn, I.M.M., Bartels, K.C.M., de Koning, H.J., &
Oudkerk, M. (2000). First experiences in screening women at high risk for breast
cancer with MR imaging. Breast Cancer Research and Treatment, 63, 53-60.
Ubel P.A., & Loewenstein, G. (1997). The role of decision analysis in informed
consent: choosing between intuition and systematicity. Social Science & Medicine,
44, 647-656.

72

University of Ottawa, Ottawa Health Decision Centre at eh Ottawa Health Research
Institute. (2006). User Manual: Decisional Conflict Scale(s). Retrieved July 7,
2007, from
http://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_DecConflict2006.pdf
University of Ottawa, Ottawa Health Decision Centre at eh Ottawa Health Research
Institute. (1996). User Manual: Decision Regret Scale. Retrieved July 7, 2007,
from http://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Regret_Scale.pdf
U.S. Preventative Services Task Force. (2005). Screening for breast cancer. Retrieved
June 19, 2006, from www.ahrq.gov/clinic/usptf/uspsbrgen.htm
van Dijk, S., Otten, W., Zoeteweij, M.W., Timmermans, D.R.M., van Asperen, C.J.,
Breuning, et al. (2003). Genetic counseling and the intention to undergo prophylactic
mastectomy: Effects of a breast cancer risk assessment. British Journal of Cancer,
88, 1675-1681.
van Oostrom, I., Merijers-Heijboer, H., Lodder, L.N., Duivenvoorden, H.J., van Gool,
A.R., Seynaeve, C., et al. (2003). Long-term psychological impact of carrying a
BRCA1/2 mutation and prophylactic surgery: A 5-year follow-up study. Journal of
Clinical Oncology, 21, 3867-3874.
van Roosmalen, M.S., Stalmeier, P.F.M., Verhoef, L.C.G., Hoekstra-Weebers, J.E.H.M.,
Oosterwijk, J.C., Hoogerbruggae, N., et al. (2004a). Randomized trial of a decision
aid an its timing for women being tested for BRCA1/2 mutation. British Journal of
Cancer, 90, 333-342.
van Roosmalen, M.S., Stalmeier, P.F.M., Verhoef, L.C.G., Hoekstra-Weebers, J.E.H.M.,
Oosterwijk, J.C., Hoogerbruggae, N., et al. (2004b). Randomized trial of a shared
decision-making intervention consisting of trade-offs and individualized treatment
information for BRCA1/2 mutation carriers. Journal of Clinical Oncology, 22, 32933301.
Warner, E., Plewes, D.B., Hill, K.A., Causer, P.A., Zubovits, J.T., Jong, R.A., et al.
(2004). Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic
resonance imaging, ultrasound, mammography, and clinical breast examination.
Journal of American Medical Association, 292, 1317-1325.
Whittemore, A.S., Gong, G., & Itnyre, J. (1997). Prevelance and contribution of BRCA1
mutation in breast cancer and ovarian cancer: Results of three US population-based
case-control studies of ovarian cancer. American Journal of Human Genetics, 60,
496-504.
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., & Mangion, J. (1995).
Identification of the breast cancer susceptibility gene BRCA2. Nature, 378, 789-792.
73

Appendices

74

Appendix A: Pilot Participant Telephone Script
Hello, my name is Heidi King and I am calling from the Moffitt Cancer Center. Sue
Friedman provided me with your name as someone who might be interested in
completing a survey we are piloting for one of our new studies.
Have you spoken with Sue Friedman?
Is now a good time to tell you a bit more about the study?
We are interested in finding out how women who have tested positive for the BRCA1/2
gene mutation go about making decisions to reduce their risk of breast cancer. The
survey is posted on-line. Before we open the study up to the general population, we
would like to verify the length of time it takes to complete the study, as well make sure
all the questions are clearly stated.
Does this sound like something you might be interested in?

I have a few questions to ask you to ensure this pilot study is a good fit for you.
1. Have you tested positive for the BRCA1/2 gene mutation? _________Must be
+.
2. When was that? _________Must be at one year or more ago.
3. Have you ever been diagnosed with any type of cancer? _________
Only exception is basal cell cancer.
4. Have you had a prophylactic oophorectomy (the removal of healthy ovaries in
order to reduce your risk of cancer)? _________ Must be ‘no’.
5. May I ask your age? __________Must be 18 or older.
6. Are you comfortable reading English?________
7. Do you have access to the Internet?________
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Appendix B: Informed Consent for Pilot Study

Informed Consent Form
Social and Behavioral Sciences
University of South Florida
Researchers at the University of South Florida (USF) study many topics. We want to
learn more about how women who are BRCA1/2 gene mutation carriers go about making
decisions about reducing their risk of breast cancer. To do this, we need the help of
people who agree to take part in research studies.
Title of research study: Pilot Study for Risk Reduction Decision Making in Women
with BRCA1/2 Gene Mutations
Person in charge of study: Paul Jacobsen, PhD
Study staff who can act on behalf of the person in charge: Heidi M. King, MA
Where the study will be done: H. Lee Moffitt Cancer Center
General Information about the Research Study
The purpose of this pilot study is to verify the length of time it takes to complete the
survey on how women who are BRCA1/2 gene mutation carriers go about making
decisions about whether or not to undergo prophylactic mastectomies (surgical removal
of healthy breast tissue in order to reduce the risk of breast cancer) to reduce their risk of
breast cancer. In addition, we need to ensure that the wording of all questions are clearly
stated and fully understood by individuals completing the survey.
Plan of Study
If you agree to participate, you will be asked to complete a one-time, on-line
questionnaire that does not ask for identifying information beyond your birthday and
general demographic information. It should take you approximately 25 minutes to
complete this on-line survey. Then a researcher will call you on the phone to go over the
items to ensure that they were clearly stated.
Payment for Participation
There will be no financial compensation for participating in this study.
Benefits of Being a Part of this Research Study
You will not benefit directly by participating. However, the information you provide will
help ensure that the survey is clearly worded prior to being disseminated.
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Appendix B: Informed Consent for Pilot Study (Continued)
Risks of Being a Part of this Research Study
We do not foresee any risk to you in participating in this study.
Confidentiality of Your Records
The information provided will be kept confidential to the extent feasible using the
Internet. All electronic study data will be password protected with access restricted to
approved personnel. However, certain people may need to see your study records. By
law, anyone who looks at your records must keep them confidential. The only people
who will be allowed to see these records are:
•

Study staff.

•

People who make sure that we are doing the study in the right way. They also
make sure that we protect your rights and safety:
o The USF Institutional Review Board (IRB)
o The United States Department of Health and Human Services (DHHS)

" Volunteering to be Part of this Research Study
Your decision to participate in this research study is completely voluntary. You are free
to participate in this research study or to withdraw at any time. If you to choose not to
participate, or if you withdraw, there will be no penalty or loss.
" Questions and Contacts
o If you have any questions about this research study, contact Heidi King,
MA at
1-800-456-3434 X4606 or Dr. Paul Jacobsen at 813-632-1810.
o If you have questions about your rights as a person who is taking part in a
research study, you may contact a member of the Division of Research
Compliance at the University of South Florida at 813-974-5638.
Consent to Take Part in this Research Study
It is up to you. You can decide if you want to take part in this study.
I freely give my consent to take part in this study. I understand that this is research.
I have received a copy of this consent form.
___________________________________________________________
Signature Printed Name Date
of Person taking part in study of Person taking part in study
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Appendix B: Informed Consent for Pilot Study (Continued)
Statement of Person Obtaining Informed Consent
I have carefully explained to the person taking part in the study what he or she can
expect.
The person who is giving consent to take part in this study
• Understands the language that is used.
• Reads well enough to understand this form. Or is able to hear and understand
when the form is read to him or her.
• Does not have any problems that could make it hard to understand what it means
to take part in this study.
• Is not taking drugs that make it hard to understand what is being explained.
To the best of my knowledge, when this person signs this form, he or she understands:
• What the study is about.
• What needs to be done.
• What the potential benefits might be.
• What the known risks might be.
• That taking part in the study is voluntary.
________________________
Signature of Investigator
or authorized research
investigator designated by
the Principal Investigator

________________________
Printed Name of Investigator
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___________
Date

Appendix C: First Website Screen--Eligibility Criteria
Study of Risk Reduction Decision Making in Women with BRCA1/2 Gene Mutations
The purpose of this study is to learn more about how women who are BRCA1/2 gene
mutation carriers go about making decisions about ways to reduce their risk of breast
cancer. You will be asked to complete an on-line survey that takes approximately 25
minutes. Your participation in this study is anonymous to the extent possible using the
Internet.
To participate in this study, you must meet all of the following conditions:
•
•
•
•
•
•
•
•

You are a woman.
You underwent genetic testing for the BRCA1/2 gene mutation one year or more
ago.
You have tested positive for the BRCA1/2 gene mutation.
You have never been diagnosed with breast cancer.
You have never been diagnosed with any other type of cancer (with the exception
of basal cell skin cancer).
You have not undergone a prophylactic oophorectomy (surgical removal of
healthy ovaries in order to reduce the risk of breast and/or ovarian cancers).
You are at least 18 years old.
You are able to read and understand English.
CLICK HERE IF YOU
CLICK HERE IF YOU
DO NOT MEET
MEET ALL
ALL OF THESE
OF THESE CONDITIONS
CONDITIONS

Ineligible Message:
Thank you for your interest. However, at this time, you do not meet eligibility criteria for
this study. Have a great day!
Eligible Message:
You are eligible to participate in the study! Please read through the full description of the
study provided below to become informed about any risks and benefits as a result of your
participation. Please click on “Agree” or “Do Not Agree” at the bottom of the page once
you have read through the entire informed consent.
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Appendix D: Informed Consent for Study Participants

Informed Consent Form
Social and Behavioral Sciences
University of South Florida
Researchers at the University of South Florida (USF) study many topics. We want to
learn more about how women who are BRCA1/2 gene mutation carriers go about making
decisions about reducing their risk of breast cancer. To do this, we need the help of
people who agree to take part in research studies. You are being asked to participate
because you have met the following eligibility criteria:
1) You are a woman.
2) You have tested positive for the BRCA1/2 gene mutation one year or more
ago.
3) You have never been diagnosed with breast cancer, or any other type of
cancer (with the exception of basal skin cancer).
4) You have not undergone a prophylactic oophorectomy (surgical removal of
healthy ovaries in order to reduce the risk of breast and/or ovarian cancers).
5) You are at least 18 years old.
6) You are able to read and understand English.
Title of research study: Risk Reduction Decision Making in Women with
BRCA1/2 Gene Mutations
Person in charge of study: Paul Jacobsen, PhD
Study staff who can act on behalf of the person in charge: Heidi M. King, MA
Where the study will be done: H. Lee Moffitt Cancer Center
General Information about the Research Study
The purpose of this research study is to learn more about how women who are BRCA1/2
gene mutation carriers go about making decisions about whether or not to undergo
prophylactic mastectomies (surgical removal of healthy breast tissue in order to reduce
the risk of breast cancer) to reduce their risk of breast cancer.
Plan of Study
If you agree to participate, you will be asked to complete a one-time, on-line
questionnaire that does not ask for identifying information beyond your birthday and
general demographic information. It should take you approximately 25 minutes to
complete this on-line survey.
Payment for Participation
There will be no financial compensation for participating in this study.
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Appendix D: Informed Consent for Study Participants (Continued)
Benefits of Being a Part of this Research Study
You will not benefit directly by participating. However, the information you provide will
help researchers better understand decision making in BRCA1/2 mutation carriers.
Risks of Being a Part of this Research Study
We do not foresee any risk to you in participating in this study.
Confidentiality of Your Records
You will be anonymously participating in this study to the extent feasible using the
Internet. All electronic study data will be password protected with access restricted to
approved personnel.
However, certain people may need to see your study records. By law, anyone who looks
at your records must keep them confidential. The only people who will be allowed to see
these records are:
•

Study staff.

•

People who make sure that we are doing the study in the right way. They also
make sure that we protect your rights and safety:
o The USF Institutional Review Board (IRB)
o The United States Department of Health and Human Services (DHHS)

We may publish what we find out from this study. However, the data obtained from you
will be combined with data from other people in the publication. We will not be
collecting or disclosing any identifying information about you.
" Volunteering to be Part of this Research Study
Your decision to participate in this research study is completely voluntary. You are free
to participate in this research study or to withdraw at any time. If you to choose not to
participate, or if you withdraw, there will be no penalty or loss.
" Questions and Contacts
o If you have any questions about this research study, contact Heidi King,
MA at 1-800-456-3434 X4606 or Dr. Paul Jacobsen at 813-632-1810.
o If you have questions about your rights as a person who is taking part in a
research study, you may contact a member of the Division of Research
Compliance at the University of South Florida at 813-974-5638.
By clicking the “agree” button below, you indicate that you have read and understood the
information above including any possible risks and benefits of participation. You also
indicate that you agree to participate in this study.
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Appendix E: General Background Information

1. Today's date:
2. Birth date:

ρρ/ρρ/ρρρρ (month/day/year)

ρρ /ρρ/ ρρρρ (month/day/year)

3. Height:

ρ (ft) ρρ (in)

4. Weight:

ρ ρ ρ (pounds)

5. Are you:
ρ Hispanic or Latino
ρ Not Hispanic or Latino
6. Race:
ρ American Indian or Alaska Native
ρ Asian
ρ Black or African American

ρ Native Hawaiian/other Pacific Islander
ρ White
ρ More than one race

7. Are you of Ashkenazi Jewish heritage?
ρ Yes
ρ No
8. Marital status:
ρ
ρ
ρ

Never married
Currently married
Separated

9. Number of children under 18:

ρ

ρ Divorced
Widowed

ρρ
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Appendix E: General Background Information (Continued)
`10.

Current living arrangement :
ρ
ρ
ρ

11.

How long in current living arrangement:
ρ
ρ
ρ

12.

Live alone ρ Live with roommate who is not partner
Live with spouse/partner
ρ Live with parents
Live with children (no spouse/partner) ρ Other (specify)__________

ρ Two to 5 years
ρ More than 5 years

Less than 1 month
One to 6 months
Seven months to 2 years

Highest level of school completed:
ρ Less than 7th grade
ρ Partial high school (10th or 11th grade)
ρ High School graduate

13.

ρ Partial college/specialized training
ρ College or university graduate
ρ Graduate professional training
(graduate degree)

Approximate annual gross income for your household:
ρ
ρ
ρ

Less than $ 10,000
$10,000 - $19,999
$20,000 - $ 39,999

ρ

ρ $40,000 - $59,999
$60,000 - $100,000
ρ Greater than $100,000
ρ Prefer not to answer

Genetic Testing Information
14. Who referred you for genetic testing?
No one, I referred myself
A family member
An oncologist
A surgeon
A primary care provider (family physician)
A gynecologist
A nurse
Other (describe _________________________________)
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Appendix E: General Background Information (Continued)
15. When did you receive your genetic test results?

Month

Year

16. Did you share these results with your primary care doctor?
No
Yes

Family History for Breast and/or Ovarian Cancer
17. Have any of your biological first degree relatives (i.e., your mother, your sister(s), or
your daughter(s)) ever had breast cancer?
No (if checked, skip to item 18)
Don’t know (if checked, skip to item 18)
Yes
17a. Who?

"

One First Degree Relative
Two First Degree Relatives
Three First Degree Relatives
More than Three First Degree Relatives

!
17b. Were any of them first told they had breast cancer at before age 50?
No
Yes

!
17c. How close is/was your relationship with this relative (if more than one relative had
breast cancer, please rate for the relative you feel/felt closest to)?
Not at all close
Somewhat close
Very close
Extremely close
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Appendix E: General Background Information (Continued)
18. Have any of your biological first degree relatives (i.e., your mother, your sister(s), or
your daughter(s)) ever had ovarian cancer?
No (if checked, skip to item 19)
Don’t know (if checked, skip to item 19)
Yes
18a. Who?

"

One First Degree Relative
Two First Degree Relatives
Three First Degree Relatives
More than Three First Degree Relatives

!
18b. Were any of them first told they had breast cancer before age 50?
No
Yes

!
18c. How close is/was your relationship with this relative (if more than one relative had
ovarian cancer, please rate for the relative you feel/felt closest to)?
Not at all close
Somewhat close
Very close
Extremely close
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Appendix E: General Background Information (Continued)
Risk-Reducing Options Chosen
19. Have you undergone a prophylactic mastectomy (surgical removal of healthy breast
tissue in order to reduce the risk of breast cancer)?
No (if checked, go to Item 20).
Yes (if checked, go to Item 19a)
19a. When did you undergo prophylactic mastectomy?
Month

Year

Perceived Risk
19b. Prior to undergoing prophylactic mastectomy, how likely did you think you were to
have breast cancer during your lifetime?
Extremely unlikely
Very unlikely
Somewhat unlikely
Somewhat likely
Very likely
Extremely likely
19c. Prior to undergoing prophylactic mastectomy, what did you think your chances were of
having breast cancer in your lifetime compared to other women your age?
Much higher
Somewhat higher
About the same
Somewhat lower

Much lower
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Appendix E: General Background Information (Continued)
20. At this time, how likely do you think you are to have breast cancer during your lifetime?
Extremely unlikely
Very unlikely
Somewhat unlikely
Somewhat likely
Very likely
Extremely likely
21. At this time, what do you think your chances are of having breast cancer in your lifetime
compared to other women your age?
Much higher
Somewhat higher
About the same
Somewhat lower

Much lower PM

Group now jumps to Item 34
Intentions

22. In the next 6 months, how likely are you to undergo prophylactic mastectomy?

1

2

3

4

5

Extremely
Unlikely

Unlikely

Not Sure

Likely

Extremely
Likely
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Appendix E: General Background Information (Continued)
Surveillance Behaviors
23. A breast self-examination involves examining your own breasts to help identify any
lumps or changes in your normal breast tissue. Have you performed a breast selfexamination for the detection of breast cancer in the past month? (check one box)
No
Yes
24. How often have you performed breast self-examination for the detection of breast
cancer in the past year?
Not at all
Less than once a month
About once a month
More than once a month
25. How often do you plan on doing a breast self-examination in the next year?
Not at all
Less than once a month
About once a month
More than once a month
26. How confident do you feel in your ability to perform breast self-examination? (check
one box)
Not at all confident
A little confident
Fairly confident
Very confident
Extremely confident
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Appendix E: General Background Information (Continued)
27. Please indicate the extent to which you agree or disagree with each of the following
statements about a breast self-examination as they apply to women who are BRCA1 or
BRCA2 positive:
Strongly
Disagree

Disagree

Neither
Agree/
Disagree

Agree

Strongly
Agree

a. A woman would be less anxious
if she did a monthly breast selfexamination………………………
b. If a woman does a breast
selfexamination, she may find lumps
before her regular check-up.
c. A woman would gain a lot by doing
breast self-examinations…...
d. Breast self-examinations can
prevent future
problems……………...
e. Breast self-examinations will
improve a woman’s
health……………………

28. Have you had a breast exam conducted by a medical professional for the detection of
breast cancer in the past year?
Yes
No - If no, why not?
No reason
My doctor(s) did not recommend it
I didn’t think I needed it

I put it off or didn’t get around to it
I couldn’t afford it
I thought it would be too painful, unpleasant, or embarrassing
I never heard of it
I didn’t have any problems or symptoms
I thought I was too young or too old to have it done
Other (please explain)
_______________________________________________)
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Appendix E: General Background Information (Continued)
29. How many breast exams conducted by a medical professional for the detection of
breast cancer have you had in the past 3 years?
(check one box)
0

1

2

3

4 or more

30. Have you had a mammogram for the detection of breast cancer in the past year?
Yes
No - If not, why not?
No reason
My doctor(s) did not recommend it
I didn’t think I needed it

I put it off or didn’t get around to it
I couldn’t afford it
I thought it would be too painful, unpleasant, or embarrassing
I never heard of it
I didn’t have any problems or symptoms
I thought I was too young or too old to have it done
Other (please explain
_______________________________________________)
31. How many mammograms for the detection of breast cancer have you had in the past 3
years?
0

1

2

3

4 or more
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Appendix E: General Background Information (Continued)
32. Have you had magnetic resonance imaging (MRI) for the detection of breast cancer
in the past year?
Yes
No - If no, why not?
No reason
My doctor(s) did not recommend it
I didn’t think I needed it

I put it off or didn’t get around to it
I couldn’t afford it
I thought it would be too painful, unpleasant, or embarrassing
I never heard of it
I didn’t have any problems or symptoms
I thought I was too young or too old to have it done
Other (please explain)
_______________________________________________
33. How many MRI’s for the detection of breast cancer have you had in the past 3 years?

0 1

2

3

4 or more
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Appendix E: General Background Information (Continued)
34. Have you ever had any cosmetic surgery on your breasts?
No (If checked, go to Item 35.)
Yes (If checked, go to 34a.)

34a. What surgery?
ρ Reconstruction following prophylactic mastectomy
ρ Breast augmentation
ρ Breast reduction
ρ Other

35. In the future, how likely are you to undergo a prophylactic oophorectomy (the
surgical removal of healthy ovaries to reduce your risk of breast cancer)?

1

2

3

4

5

Extremely
Unlikely

Unlikely

Not Sure

Likely

Extremely
Likely

Menopausal Status Questionnaire
36. Have you ever had a hysterectomy (i.e., removal of the womb)?
ρ No
ρ Yes
ρ Don't know
37.Have you ever had one or both of your ovaries removed?
ρ No, neither of my ovaries have been removed
ρ Yes, one ovary removed
ρ Yes, both ovaries removed
ρ Do not know
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Appendix E: General Background Information (Continued)
38.

Have you received any hormone replacement therapy within the past week (i.e.,
estrogen)?
ρNo
ρYes
ρDon't know

39.

Have you ever received hormone replacement therapy (i.e., estrogen)?
ρ No
ρ Yes
ρ Don't know

40.

Have you had a menstrual period within the past 3 months?
ρNo
ρYes
ρDon't know

41.

Have you had a menstrual period within the past 12 months?
ρNo
ρYes
ρDon't know

42.

Compared with 12 months ago, are your menstrual periods in the past 3 months, less
regular, about the same, or more regular?
ρI have not had a menstrual period within the past 3 months
ρLess regular
ρAbout the same
ρMore regular
ρDon't know

43.Are you currently taking Tamoxifen / Nolvadex?
ρNo
ρYes
44.Are you currently taking Raloxifine / Evista?
ρNo
ρYes
45.Are you currently taking Anastrazole / Arimidex?
ρNo
ρYes
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Appendix E: General Background Information (Continued)
46.Are you currently taking Letrezole / Femara?
ρNo
ρYes
47.Are you currently taking Toremifine / Fareston?
ρNo
ρYes
48.Are you currently taking Exemstrane / Aromasin?
ρNo
ρYes
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Appendix F: Decisional Balance Scale for Prophylactic Mastectomy
Below is a list of issues that a woman who is BRCA1 or BRCA2 positive might have
considered when deciding whether or not to pursue prophylactic mastectomy. Think
back to the time after you received your BRCA1 or BRCA2 results and were deciding
about whether to undergo prophylactic mastectomy. Think about what season of the year
it was. Think about the month it was. Think about the major holidays that occurred
around this time. Most importantly, try to remember how were feeling, as well as what
you were thinking around the time you considered whether or not to undergo a
prophylactic mastectomy. Please read each item below and indicate the degree to which
you believe you agreed or disagreed with each item when considering prophylactic
mastectomy.
At the time I was deciding about
prophylactic mastectomy….

Strongly
Agree

49A. I believed prophylactic mastectomy
would substantially reduce my risk
of breast cancer.
49B. I was concerned about how
prophylactic
mastectomy would affect my
physical
appearance.
49C. I thought I would worry much less
about getting breast cancer if I
had prophylactic mastectomy.
49D. I was not seriously concerned about
the
surgical risks involved with
prophylactic mastectomy.
49E. I believed having prophylactic
mastectomy would not affect
how I viewed my body.
49F. I believed the recovery period
following prophylactic
mastectomy would be too
physically draining for me.
49G. I believed having a prophylactic
mastectomy would negatively
affect my sex life.
49H. I believed, following prophylactic
mastectomy, I would still be
concerned
with my risk for breast cancer.
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Agree

Neither
Agree
Or
Disagree

Disagree

Strongly
Disagree

Appendix G: Physician Input
50. Did a doctor give his/her opinion to you about the risk-reducing strategy (for example,
prophylactic mastectomy or mammography) you should choose?
ρ No (Go to .)
ρ Yes (Go to # 50a)
50A. Did more than one doctor give his/her opinion about the risk-reducing strategy you should
choose?
ρ No (Go to #50C)
ρ Yes (Go to #50B)
50B. How many doctors made recommendations?
234

ρ ρρ

What did each doctor recommend?
50C. Doctor #1 most strongly recommended:
ρ Surveillance (e.g., breast self-exam, clinical breast exam, mammography)
ρ Prophylactic mastectomy
ρ Chemoprevention (i.e., use of medications to prevent breast cancer)
50D. Doctor #2 most strongly recommended:
ρ Surveillance (e.g., breast self-exam, clinical breast exam, mammography)
ρ Prophylactic mastectomy
ρ Chemoprevention (i.e., use of medications to prevent breast cancer)
50E. Doctor #3 most strongly recommended:
ρ Surveillance (e.g., breast self-exam, clinical breast exam, mammography)
ρ Prophylactic mastectomy
ρ Chemoprevention (i.e., use of medications to prevent breast cancer)
50F. Doctor #4 most strongly recommended:
ρ Surveillance (e.g., breast self-exam, clinical breast exam, mammography)
ρ Prophylactic mastectomy
ρ Chemoprevention (i.e., use of medications to prevent breast cancer)
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Appendix H: Cancer Worry Scale

During the past month . . .
51. How often have you been concerned about getting breast cancer?

Not at all
or Rarely

Sometimes

Often

A lot

52. How often have you thought about your own chances of having breast cancer?

Not at all
or Rarely

Sometimes

Often

A lot

53. How often have thoughts about breast cancer affected your mood?

Not at all
or Rarely

Sometimes

Often

A lot

54. How often have thoughts about breast cancer affected your ability to perform your
daily activities?

Not at all
or Rarely

Sometimes

Often
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A lot

Appendix I: Retrospective Cancer Worry Scale

Think back to the time after you received your BRCA1 or BRCA2 results. Think about
what season of the year it was. Think about the month it was. Think about the major
holidays that occurred around this time. Most importantly, try to remember how you
were feeling, as well as what you were thinking around the time you received your
BRCA1 or BRCA2 results.

One month after receiving your BRCA1/2 results. . .
55a. How often were you concerned about getting breast cancer?

Not at all
or Rarely

Sometimes

Often

A lot

55b. How often did you think about your own chances of having breast cancer?

Not at all
or Rarely

Sometimes

Often

A lot

55c. How often did thoughts about breast cancer affected your mood?

Not at all
or Rarely

Sometimes

Often

A lot

55d. How often did thoughts about breast cancer affected your ability to perform your
daily activities?

Not at all
or Rarely

Sometimes

Often
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A lot

Appendix J: Decision Conflict Scale
56. Think back to the time after you received your BRCA1 or BRCA2 results and were
deciding about whether to undergo prophylactic mastectomy. Think about what
season of the year it was. Think about the month it was. Think about the major
holidays that occurred around this time. Most importantly, try to remember how
you were feeling, as well as what you were thinking around the time you
considered whether or not to undergo a prophylactic mastectomy. What did you
think about the risk-reducing options for breast cancer (e.g., prophylactic
mastectomy, mammography, MRI)?

Strongly
Agree
56a. I knew which options were
available to me.
56b. I knew the benefits of each
option.
56c. I knew the risks and side effects
of each option.
56d. I was clear about which benefits
mattered most to me.
56e. I was clear about which risks and
side effects mattered most.
56f. I was clear about which was more
important to me (the benefits or
the risks and side effects).

99

Agree

Neither
Agree
Or
Disagree

Disagree

Strongly
Disagree

Appendix J: Decision Conflict Scale (Continued)
57 How did you feel about making a decision about which risk-reducing option to
choose?

Strongly
Agree

a. I had enough support from others to
make a choice.
b. I chose without pressure from others.
c. I had enough advice to make a choice.
d. I was clear about the best choice for
me.
e. I felt sure about what to choose.
f. This decision was easy for me to make.
g. I felt I made an informed choice.
h. My decision shows what is important
to me.
i. I expect to stick with my decision.
j. I am satisfied with my decision.
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Neither
Agree Or
Disagree
Agree

Disagree

Strongly
Disagree

Appendix K: Decision Regret Scale
58.

Please reflect on the decision you have made about whether or not to undergo
prophylactic mastectomy. Please show how strongly you agree or disagree with
these statements by selecting the response that best fits your views about your
decision.

58a. It was the right decision..................... ρρρρρ
58b. I regret the choice that was made....... ρρρρρ
58c. I would go for the same choice if I
had to do it over again......................... ρρρρρ
58d. The choice did me a lot of harm ........ ρρρρρ
58e. The decision was a wise one.............. ρρρρρ
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Appendix L: Center for Epidemiologic Studies, Depression Scale (CES-D)
For each statement below, make an “X” in the box which best describes how often you felt or
behaved this way. DURING THE PAST WEEK, INCLUDING TODAY.

59a. I was bothered by things that
usually don't bother me.
59b. I did not feel like eating; my
appetite was poor.
59c. I felt that I could not shake off
the blues even with help from
my family or friends.
59d. I felt that I was just as good as
other people.
59e. I had trouble keeping my mind
on what I was doing.
59f. I felt depressed.
59g. I felt that everything I did was
an effort.
59h. I felt hopeful about the future.
59i. I thought my life had been a
failure.
59j. I felt fearful.

None of the
Time

A Little
of the
Time

A Moderate
Amount of
Time

Most of
the
Time

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ
ρ

ρ
ρ

ρ
ρ

ρ
ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ

ρ
ρ

ρ
ρ

ρ
ρ

ρ
ρ

59k. My sleep was restless.
59l. I was happy.
59m. I talked less than usual.
59n. I felt lonely.
59o. People were unfriendly.
59p. I enjoyed life.
59q. I had crying spells.
59r. I felt sad.
59s. I felt that people disliked me.
59t. I could not “get going.”
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Appendix M: Miller Behavioral Style Scale
60.

Vividly imagine that you are afraid of the dentist and have to get some dental
work done. Which of the following would you do? Check all of the statements
that might apply to you.
_____ I would ask the dentist exactly what he was going to do.
_____ I would take a tranquilizer or have a drink before going.
_____ I would try to think about pleasant memories.
_____ I would want the dentist to tell me when I would feel pain.
_____ I would try to sleep.
_____ I would watch all the dentist’s movements and listen for the sound of his drill.
_____ I would watch the flow of water from my mouth to see if it contained blood.
_____ I would do mental puzzles in my mind.

61.

Vividly imagine that you are being held hostage by a group of armed terrorists in
a public building. Which of the following would you do? Check all of the
statements that might apply to you.

_____ I would sit by myself and have as many daydreams and fantasies as I could.
_____ I would stay alert and try to keep myself from falling asleep.
_____ I would exchange life stories with the other hostages.
_____ If there was a radio present, I would stay near it and listen to the bulletins
what the police were doing.
_____ I would watch every movement of my captors and keep an eye on their
weapons.
_____ I would try to sleep as much as possible.
_____ I would think about how nice it’s going to be when I get home.
_____ I would make sure I knew where every possible exit was.
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Appendix M: Miller Behavioral Style Scale (Continued)
62.

Vividly imagine that, due to a large drop in sales, it is rumored that several
people in your department at work will be laid off. Your supervisor has turned
in an evaluation of your work for the past year. The decision about lay-offs has
been made and will be announced in several days. Check all of the statements
that might apply to you.

_____ I would talk to my fellow workers to see if they knew anything about what the
supervisor’s evaluation of me said.
_____ I would review the list of duties for my present job and try to figure out if I
had fulfilled them all.
_____ I would go to the movies to take my mind off things.
_____ I would try to remember any arguments or disagreements I might have had
with the supervisor that would have lowered his opinion of me.
_____ I would push all thoughts of being laid off out of my mind.
_____ I would tell my spouse that I’d rather not discuss my chances of being laid off.
_____ I would try to think which employees in my department the supervisor might
have thought had done the worst job.
_____ I would continue doing my work as if nothing special was happening.
63. Vividly imagine that you are on an airplane, thirty minutes from your destination,
when the plane unexpectedly goes into a deep dive and then suddenly levels off.
After a short time, the pilot announces that nothing is wrong, although the rest of
the ride may be rough. You, however, are not convinced that all is well. Check
all of the statements that might apply to you.
_____ I would carefully read the information provided about safety features in the
plane and make sure I knew where the emergency exits were.
_____ I would make small talk with the passenger beside me.
_____ I would watch the end of the movie, even if I had seen it before.
_____ I would call the stewardess and ask her exactly what the problem was.
_____ I would order a drink or tranquilizer from the stewardess.
_____ I would listen carefully to the engines for unusual noises and would watch the
crew to see if their behavior was out of the ordinary
_____ I would talk to the passenger beside me about what might be wrong.
_____ I would settle down and read a book or magazine or write a letter.
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